{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T03:07:37Z","timestamp":1792552057868,"version":"4.5.0"},"reference-count":385,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,8,5]],"date-time":"2021-08-05T00:00:00Z","timestamp":1628121600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Resistance Updates"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1016\/j.drup.2021.100778","type":"journal-article","created":{"date-parts":[[2021,8,6]],"date-time":"2021-08-06T04:55:23Z","timestamp":1628225723000},"page":"100778","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":96,"special_numbering":"C","title":["Metal- and metalloid-based compounds to target and reverse cancer multidrug resistance"],"prefix":"10.1016","volume":"58","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3370-208X","authenticated-orcid":false,"given":"Andreia","family":"Valente","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7412-3685","authenticated-orcid":false,"given":"Ana","family":"Podolski-Reni\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabella","family":"Poetsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2982-5324","authenticated-orcid":false,"given":"Nenad","family":"Filipovi\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2896-6993","authenticated-orcid":false,"given":"\u00d3scar","family":"L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6776-4062","authenticated-orcid":false,"given":"Iztok","family":"Turel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6401-8646","authenticated-orcid":false,"given":"Petra","family":"Heffeter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.drup.2021.100778_bib0005","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1038\/sj.onc.1210220","article-title":"The Bcl-2 apoptotic switch in cancer development and therapy","volume":"26","author":"Adams","year":"2007","journal-title":"Oncogene"},{"key":"10.1016\/j.drup.2021.100778_bib0010","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1021\/acs.organomet.6b00197","article-title":"Arene Osmium Complexes with Ethacrynic Acid-Modified Ligands: Synthesis, Characterization, and Evaluation of Intracellular Glutathione S-Transferase Inhibition and Antiproliferative Activity","volume":"35","author":"Agonigi","year":"2016","journal-title":"Organometallics"},{"key":"10.1016\/j.drup.2021.100778_bib0015","doi-asserted-by":"crossref","first-page":"6504","DOI":"10.1021\/acs.inorgchem.5b00802","article-title":"Synthesis and Antiproliferative Activity of New Ruthenium Complexes with Ethacrynic-Acid-Modified Pyridine and Triphenylphosphine Ligands","volume":"54","author":"Agonigi","year":"2015","journal-title":"Inorg Chem"},{"key":"10.1016\/j.drup.2021.100778_bib0020","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1038\/sj.bjc.6600290","article-title":"In vitro and in vivo activity and cross resistance profiles of novel ruthenium (II) organometallic arene complexes in human ovarian cancer","volume":"86","author":"Aird","year":"2002","journal-title":"Brit J Cancer"},{"key":"10.1016\/j.drup.2021.100778_bib0025","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.3390\/molecules24101995","article-title":"NAMI-A and KP1019\/1339, Two Iconic Ruthenium Anticancer Drug Candidates Face-to-Face: A Case Story in Medicinal Inorganic Chemistry","volume":"24","author":"Alessio","year":"2019","journal-title":"Molecules"},{"key":"10.1016\/j.drup.2021.100778_bib0030","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.canlet.2017.04.041","article-title":"Preclinical anti-cancer activity and multiple mechanisms of action of a cationic silver complex bearing N-heterocyclic carbene ligands","volume":"403","author":"Allison","year":"2017","journal-title":"Cancer Lett"},{"key":"10.1016\/j.drup.2021.100778_bib0035","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1146\/annurev.pharmtox.39.1.361","article-title":"Biochemical, cellular, and pharmacological aspects of the multidrug transporter","volume":"39","author":"Ambudkar","year":"1999","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1016\/j.drup.2021.100778_bib0040","doi-asserted-by":"crossref","first-page":"100658","DOI":"10.1016\/j.drup.2019.100658","article-title":"Advanced technological tools to study multidrug resistance in cancer","volume":"48","author":"Andrei","year":"2020","journal-title":"Drug Resist Updat"},{"key":"10.1016\/j.drup.2021.100778_bib0045","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1002\/cmdc.200700209","article-title":"Organometallic ruthenium inhibitors of glutathione-S-transferase P1-1 as anticancer drugs","volume":"2","author":"Ang","year":"2007","journal-title":"ChemMedChem"},{"key":"10.1016\/j.drup.2021.100778_bib0050","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1021\/ja0432618","article-title":"Rational design of platinum(IV) compounds to overcome glutathione-S-transferase mediated drug resistance","volume":"127","author":"Ang","year":"2005","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.drup.2021.100778_bib0055","doi-asserted-by":"crossref","first-page":"3854","DOI":"10.1002\/anie.200900185","article-title":"Rational Design of an Organometallic Glutathione Transferase Inhibitor","volume":"48","author":"Ang","year":"2009","journal-title":"Angew Chem Int Ed"},{"key":"10.1016\/j.drup.2021.100778_bib0060","doi-asserted-by":"crossref","first-page":"12888","DOI":"10.1039\/D0SC04082G","article-title":"Metallodrugs are unique: opportunities and challenges of discovery and development","volume":"11","author":"Anthony","year":"2020","journal-title":"Chem Sci"},{"key":"10.1016\/j.drup.2021.100778_bib0065","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/S0278-5846(03)00016-2","article-title":"Apoptotic signaling cascades","volume":"27","author":"Ashe","year":"2003","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"10.1016\/j.drup.2021.100778_bib0070","doi-asserted-by":"crossref","first-page":"100645","DOI":"10.1016\/j.drup.2019.100645","article-title":"The multi-factorial nature of clinical multidrug resistance in cancer","volume":"46","author":"Assaraf","year":"2019","journal-title":"Drug Resist Updat"},{"key":"10.1016\/j.drup.2021.100778_bib0075","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.drup.2014.10.002","article-title":"The folate receptor as a rational therapeutic target for personalized cancer treatment","volume":"17","author":"Assaraf","year":"2014","journal-title":"Drug Resist Updat"},{"key":"10.1016\/j.drup.2021.100778_bib0080","doi-asserted-by":"crossref","first-page":"14854","DOI":"10.1021\/jacs.5b10182","article-title":"A Pt(IV) Pro-drug Preferentially Targets Indoleamine-2,3-dioxygenase, Providing Enhanced Ovarian Cancer Immuno-Chemotherapy","volume":"137","author":"Awuah","year":"2015","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.drup.2021.100778_bib0085","doi-asserted-by":"crossref","first-page":"13405","DOI":"10.1002\/anie.202102266","article-title":"Interfering with Metabolic Profile of Triple-Negative Breast Cancers Using Rationally Designed Metformin Prodrugs","volume":"60","author":"Babak","year":"2021","journal-title":"Angew Chem Int Ed"},{"key":"10.1016\/j.drup.2021.100778_bib0090","doi-asserted-by":"crossref","first-page":"426","DOI":"10.3109\/10715762.2015.1136062","article-title":"Induction of intrinsic and extrinsic apoptosis through oxidative stress in drug-resistant cancer by a newly synthesized Schiff base copper chelate","volume":"50","author":"Banerjee","year":"2016","journal-title":"Free Radic Res"},{"key":"10.1016\/j.drup.2021.100778_bib0095","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.biopha.2016.08.056","article-title":"A copper chelate induces apoptosis and overcomes multidrug resistance in T-cell acute lymphoblastic leukemia through redox imbalance and inhibition of EGFR\/PI3K\/Akt expression","volume":"84","author":"Banerjee","year":"2016","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.drup.2021.100778_bib0100","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.drup.2017.05.002","article-title":"Targeted nanomedicine for cancer therapeutics: Towards precision medicine overcoming drug resistance","volume":"31","author":"Bar-Zeev","year":"2017","journal-title":"Drug Resist Updat"},{"key":"10.1016\/j.drup.2021.100778_bib0105","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.2174\/0929867323666161214114948","article-title":"Combination Platinum-based and DNA Damage Response-targeting Cancer Therapy: Evolution and Future Directions","volume":"24","author":"Basourakos","year":"2017","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.drup.2021.100778_bib0110","doi-asserted-by":"crossref","first-page":"2752","DOI":"10.1002\/jcp.26091","article-title":"Genetic variation in the DNA repair pathway as a potential determinant of response to platinum-based chemotherapy in breast cancer","volume":"233","author":"Beheshti","year":"2018","journal-title":"J Cell Physiol"},{"key":"10.1016\/j.drup.2021.100778_bib0115","doi-asserted-by":"crossref","first-page":"9046","DOI":"10.1002\/chem.200801032","article-title":"In vitro anticancer activity and biologically relevant metabolization of organometallic ruthenium complexes with carbohydrate\u2010based ligands","volume":"14","author":"Berger","year":"2008","journal-title":"Chem. Eur. J."},{"key":"10.1016\/j.drup.2021.100778_bib0120","first-page":"3459","article-title":"Thioredoxin and thioredoxin reductase gene expression in human tumors and cell lines, and the effects of serum stimulation and hypoxia","volume":"16","author":"Berggren","year":"1996","journal-title":"Anticancer res"},{"key":"10.1016\/j.drup.2021.100778_bib0125","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1111\/bph.13422","article-title":"The Warburg effect and drug resistance","volume":"173","author":"Bhattacharya","year":"2016","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.drup.2021.100778_bib0130","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1016\/S0006-2952(02)00981-4","article-title":"Drug-resistant human lung cancer cells are more sensitive to selenium cytotoxicity. Effects on thioredoxin reductase and glutathione reductase","volume":"63","author":"Bj\u00f6rkhem-Bergman","year":"2002","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.drup.2021.100778_bib0135","doi-asserted-by":"crossref","first-page":"8030","DOI":"10.1016\/S0021-9258(18)42403-9","article-title":"Selenodiglutathione is a highly efficient oxidant of reduced thioredoxin and a substrate for mammalian thioredoxin reductase","volume":"267","author":"Bj\u00f6rnstedt","year":"1992","journal-title":"J Biol Chem"},{"key":"10.1016\/j.drup.2021.100778_bib0140","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1021\/jm050986t","article-title":"Synthesis and in vitro antitumor activity of platinum acetonimine complexes","volume":"49","author":"Boccarelli","year":"2006","journal-title":"J Med Chem"},{"key":"10.1016\/j.drup.2021.100778_bib0145","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1021\/om5013117","article-title":"Diaminohexopyranosides as ligands in half-sandwich ruthenium(II), rhodium(III), and iridium(III) complexes","volume":"34","author":"B\u00f6ge","year":"2015","journal-title":"Organometallics"},{"key":"10.1016\/j.drup.2021.100778_bib0150","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1093\/annonc\/mdw615","article-title":"Resistance to anticancer immunity in cancer patients: potential strategies to reverse resistance","volume":"28","author":"Bonavida","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.drup.2021.100778_bib0155","doi-asserted-by":"crossref","first-page":"13719","DOI":"10.1021\/acs.jmedchem.0c01277","article-title":"Cancer Cell Resistance Against the Clinically Investigated Thiosemicarbazone COTI-2 Is Based on Formation of Intracellular Copper Complex Glutathione Adducts and ABCC1-Mediated Efflux","volume":"63","author":"Bormio Nunes","year":"2020","journal-title":"J Med Chem"},{"key":"10.1016\/j.drup.2021.100778_bib0160","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.chempr.2019.10.013","article-title":"Classification of Metal-based Drugs According to Their Mechanisms of Action","volume":"6","author":"Boros","year":"2020","journal-title":"Chem"},{"key":"10.1016\/j.drup.2021.100778_bib0165","doi-asserted-by":"crossref","first-page":"103","DOI":"10.2174\/1389557024605500","article-title":"Biomolecular targets for platinum antitumor drugs","volume":"2","author":"Bose","year":"2002","journal-title":"Mini Rev Med Chem"},{"key":"10.1016\/j.drup.2021.100778_bib0170","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.drup.2005.04.006","article-title":"Modifications of DNA by platinum complexes. Relation to resistance of tumors to platinum antitumor drugs","volume":"8","author":"Brabec","year":"2005","journal-title":"Drug Resist Updat"},{"key":"10.1016\/j.drup.2021.100778_bib0175","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1124\/mol.109.054791","article-title":"Structural Determinants of Imidazoacridinones Facilitating Antitumor Activity Are Crucial for Substrate Recognition by ABCG2","volume":"75","author":"Bram","year":"2009","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.drup.2021.100778_bib0180","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S0165-0173(01)00045-5","article-title":"Anticancer drug resistance in primary human brain tumors","volume":"35","author":"Bredel","year":"2001","journal-title":"Brain Res Brain Res Rev"},{"key":"10.1016\/j.drup.2021.100778_bib0185","doi-asserted-by":"crossref","first-page":"11330","DOI":"10.1039\/c2dt31313h","article-title":"Combining aspects of the platinum anticancer drugs picoplatin and BBR3464 to synthesize a new family of sterically hindered dinuclear complexes; their synthesis, binding kinetics and cytotoxicity","volume":"41","author":"Brown","year":"2012","journal-title":"Dalton Trans"},{"key":"10.1016\/j.drup.2021.100778_bib0190","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1039\/C7MT00334J","article-title":"Relevance of copper transporter 1 and organic cation transporters 1-3 for oxaliplatin uptake and drug resistance in colorectal cancer cells","volume":"10","author":"Bu\u00df","year":"2018","journal-title":"Metallomics"},{"key":"10.1016\/j.drup.2021.100778_bib0195","doi-asserted-by":"crossref","first-page":"100671","DOI":"10.1016\/j.drup.2019.100671","article-title":"Towards the overcoming of anticancer drug resistance mediated by p53 mutations","volume":"49","author":"Cao","year":"2020","journal-title":"Drug Resist Updat"},{"key":"10.1016\/j.drup.2021.100778_bib0200","doi-asserted-by":"crossref","first-page":"30102","DOI":"10.18632\/oncotarget.4945","article-title":"Inhibition of glucose-6-phosphate dehydrogenase sensitizes cisplatin-resistant cells to death","volume":"6","author":"Catanzaro","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.drup.2021.100778_bib0205","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1189\/jlb.0611287","article-title":"Reprogramming of TAM toward proimmunogenic type through regulation of MAP kinases using a redox-active copper chelate","volume":"91","author":"Chakraborty","year":"2012","journal-title":"J Leukoc Biol"},{"key":"10.1016\/j.drup.2021.100778_bib0210","doi-asserted-by":"crossref","first-page":"165","DOI":"10.3109\/08923973.2014.897727","article-title":"A copper chelate selectively triggers apoptosis in myeloid-derived suppressor cells in a drug-resistant tumor model and enhances antitumor immune response","volume":"36","author":"Chakraborty","year":"2014","journal-title":"Immunopharmacol Immunotoxicol"},{"key":"10.1016\/j.drup.2021.100778_bib0215","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1158\/0008-5472.CAN-12-2225","article-title":"Dose-dense chemotherapy improves mechanisms of antitumor immune response","volume":"73","author":"Chang","year":"2013","journal-title":"Cancer Res"},{"key":"10.1016\/j.drup.2021.100778_bib0220","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1242\/jcs.107.1.213","article-title":"Differential Expression of Sucrase-Isomaltase in Clones Isolated from Early and Late Passages of the Cell-Line Caco-2 - Evidence for Glucose-Dependent Negative Regulation","volume":"107","author":"Chantret","year":"1994","journal-title":"J Cell Sci"},{"key":"10.1016\/j.drup.2021.100778_bib0225","doi-asserted-by":"crossref","first-page":"e7048","DOI":"10.1371\/journal.pone.0007048","article-title":"A novel copper chelate modulates tumor associated macrophages to promote anti-tumor response of T cells","volume":"4","author":"Chatterjee","year":"2009","journal-title":"PLoS One"},{"key":"10.1016\/j.drup.2021.100778_bib0230","doi-asserted-by":"crossref","first-page":"8944","DOI":"10.1021\/acs.jmedchem.8b01420","article-title":"Correction to A Drug of Such Damned Nature. Challenges and Opportunities in Translational Platinum Drug Research","volume":"61","author":"Cheff","year":"2018","journal-title":"J Med Chem"},{"key":"10.1016\/j.drup.2021.100778_bib0235","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.ejphar.2017.09.003","article-title":"Hinokitiol copper complex inhibits proteasomal deubiquitination and induces paraptosis-like cell death in human cancer cells","volume":"815","author":"Chen","year":"2017","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.drup.2021.100778_bib0240","doi-asserted-by":"crossref","first-page":"7427","DOI":"10.1039\/C4CC00419A","article-title":"The ligation of aspirin to cisplatin demonstrates significant synergistic effects on tumor cells","volume":"50","author":"Cheng","year":"2014","journal-title":"Chem Commun"},{"key":"10.1016\/j.drup.2021.100778_bib0245","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1124\/jpet.107.126342","article-title":"Development of gallium compounds for treatment of lymphoma: gallium maltolate, a novel hydroxypyrone gallium compound, induces apoptosis and circumvents lymphoma cell resistance to gallium nitrate","volume":"322","author":"Chitambar","year":"2007","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.drup.2021.100778_bib0250","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1007\/BF00685645","article-title":"Collateral sensitivity to radiation and cis-platinum in a multidrug-resistant human leukemia cell line","volume":"37","author":"Cho","year":"1995","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.drup.2021.100778_bib0255","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.ejphar.2015.06.046","article-title":"Selenate specifically sensitizes drug-resistant cancer cells by increasing apoptosis via G2 phase cell cycle arrest without P-GP inhibition","volume":"764","author":"Choi","year":"2015","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.drup.2021.100778_bib0260","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1007\/BF02969293","article-title":"Platinum transporters and drug resistance","volume":"29","author":"Choi","year":"2006","journal-title":"Arch Pharm Res"},{"key":"10.1016\/j.drup.2021.100778_bib0265","doi-asserted-by":"crossref","first-page":"4117","DOI":"10.1039\/C6SC00268D","article-title":"Structural tuning of organoruthenium compounds allows oxidative switch to control ER stress pathways and bypass multidrug resistance","volume":"7","author":"Chow","year":"2016","journal-title":"Chem Sci"},{"key":"10.1016\/j.drup.2021.100778_bib0270","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1158\/1078-0432.CCR-07-2176","article-title":"Current status and future prospects for satraplatin, an oral platinum analogue","volume":"14","author":"Choy","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.drup.2021.100778_bib0275","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1038\/bjc.1998.352","article-title":"Anti-proliferative activity and mechanism of action of titanocene dichloride","volume":"77","author":"Christodoulou","year":"1998","journal-title":"Br J Cancer"},{"key":"10.1016\/j.drup.2021.100778_bib0280","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1039\/c3mt20260g","article-title":"Fluorescent silver(I) and gold(I)-N-heterocyclic carbene complexes with cytotoxic properties: mechanistic insights","volume":"5","author":"Citta","year":"2013","journal-title":"Metallomics"},{"key":"10.1016\/j.drup.2021.100778_bib0285","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2010.28.15_suppl.7002","article-title":"Randomized phase III study (SPEAR) of picoplatin plus best supportive care (BSC) or BSC alone in patients (pts) with SCLC refractory or progressive within 6 months after first-line platinum-based chemotherapy","volume":"28","author":"Ciuleanu","year":"2010","journal-title":"J Clini Oncol"},{"key":"10.1016\/j.drup.2021.100778_bib0290","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1054\/bjoc.2001.1751","article-title":"Activity of a trinuclear platinum complex in human ovarian cancer cell lines sensitive and resistant to cisplatin: cytotoxicity and induction and gene-specific repair of DNA lesions","volume":"84","author":"Colella","year":"2001","journal-title":"Brit J Cancer"},{"key":"10.1016\/j.drup.2021.100778_bib0295","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1039\/C7MD00109F","article-title":"Advances in indoleamine 2,3-dioxygenase 1 medicinal chemistry","volume":"8","author":"Coletti","year":"2017","journal-title":"MedChemComm"},{"issue":"2016","key":"10.1016\/j.drup.2021.100778_bib0300","doi-asserted-by":"crossref","first-page":"4251912","DOI":"10.1155\/2016\/4251912","article-title":"Redox Control of Multidrug Resistance and Its Possible Modulation by Antioxidants","author":"Cort","year":"2016","journal-title":"Oxid Med Cell Longev"},{"key":"10.1016\/j.drup.2021.100778_bib0305","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/j.ejmech.2018.12.022","article-title":"Unprecedented inhibition of P-gp activity by a novel ruthenium-cyclopentadienyl compound bearing a bipyridine-biotin ligand","volume":"163","author":"Corte-Real","year":"2019","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.drup.2021.100778_bib0310","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1007\/s00775-014-1120-y","article-title":"Anticancer activity of structurally related ruthenium(II) cyclopentadienyl complexes","volume":"19","author":"Corte-Real","year":"2014","journal-title":"J Biol Inorg Chem"},{"key":"10.1016\/j.drup.2021.100778_bib0315","doi-asserted-by":"crossref","first-page":"4629","DOI":"10.1021\/acs.inorgchem.8b00358","article-title":"Methyl-cyclopentadienyl Ruthenium Compounds with 2,2\u2019-Bipyridine Derivatives Display Strong Anticancer Activity and Multidrug Resistance Potential","volume":"57","author":"Corte-Real","year":"2018","journal-title":"Inorg Chem"},{"key":"10.1016\/j.drup.2021.100778_bib0320","first-page":"1169","article-title":"Gamma-glutamyltransferase of Cancer Cells at the Crossroads of Tumor Progression, Drug Resistance and Drug Targeting","volume":"30","author":"Corti","year":"2010","journal-title":"Anticancer Res"},{"key":"10.1016\/j.drup.2021.100778_bib0325","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1158\/0008-5472.CAN-19-1407","article-title":"Unshielding Multidrug Resistant Cancer through Selective Iron Depletion of P-Glycoprotein-Expressing Cells","volume":"80","author":"Cserepes","year":"2020","journal-title":"Cancer Res"},{"key":"10.1016\/j.drup.2021.100778_bib0330","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1002\/cmdc.201000104","article-title":"Proteins as Possible Targets for Cytotoxic trans-Platinum(II) Complexes with Aliphatic Amine Ligands: Further Exceptions to the DNA Paradigm","volume":"5","author":"Cubo","year":"2010","journal-title":"ChemMedChem"},{"key":"10.1016\/j.drup.2021.100778_bib0335","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.drup.2018.11.001","article-title":"Modulating ROS to overcome multidrug resistance in cancer","volume":"41","author":"Cui","year":"2018","journal-title":"Drug Resist Updat"},{"key":"10.1016\/j.drup.2021.100778_bib0340","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1016\/S0006-2952(00)00448-2","volume":"60","author":"Dabholkar","year":"2000","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.drup.2021.100778_bib0345","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.ejmech.2016.10.041","article-title":"Synthesis of copper and zinc 2-(pyridin-2-yl)imidazo[1,2-a]pyridine complexes and their potential anticancer activity","volume":"126","author":"Dam","year":"2017","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.drup.2021.100778_bib0350","doi-asserted-by":"crossref","first-page":"119","DOI":"10.3390\/cancers11010119","article-title":"Platinum Resistance in Ovarian Cancer: Role of DNA Repair","volume":"11","author":"Damia","year":"2019","journal-title":"Cancers"},{"key":"10.1016\/j.drup.2021.100778_bib0355","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.bbagen.2011.07.016","article-title":"The transferrin receptor and the targeted delivery of therapeutic agents against cancer","volume":"1820","author":"Daniels","year":"2012","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.drup.2021.100778_bib0360","doi-asserted-by":"crossref","first-page":"100754","DOI":"10.1016\/j.drup.2021.100754","article-title":"Therapeutic strategies to overcome taxane resistance in cancer","volume":"55","author":"Das","year":"2021","journal-title":"Drug Resist Updat"},{"key":"10.1016\/j.drup.2021.100778_bib0365","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1016\/j.febslet.2005.12.036","article-title":"Substrate recognition and transport by multidrug resistance protein 1 (ABCC1)","volume":"580","author":"Deeley","year":"2006","journal-title":"FEBS Lett"},{"key":"10.1016\/j.drup.2021.100778_bib0370","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1146\/annurev-pharmtox-010611-134529","article-title":"Drug transporters in drug efficacy and toxicity","volume":"52","author":"DeGorter","year":"2012","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1016\/j.drup.2021.100778_bib0375","doi-asserted-by":"crossref","first-page":"8477","DOI":"10.1039\/c0dt00239a","article-title":"Synthesis of hybrid transition-metalloproteins via thiol-selective covalent anchoring of Rh-phosphine and Ru-phenanthroline complexes","volume":"39","author":"den Heeten","year":"2010","journal-title":"Dalton Trans"},{"key":"10.1016\/j.drup.2021.100778_bib0380","doi-asserted-by":"crossref","first-page":"22199","DOI":"10.1073\/pnas.0912276106","article-title":"Mitaplatin, a potent fusion of cisplatin and the orphan drug dichloroacetate","volume":"106","author":"Dhar","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.drup.2021.100778_bib0385","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.drup.2017.02.001","article-title":"Novel immune check point inhibiting antibodies in cancer therapy-Opportunities and challenges","volume":"30","author":"Diesendruck","year":"2017","journal-title":"Drug Resist Updat"},{"key":"10.1016\/j.drup.2021.100778_bib0390","doi-asserted-by":"crossref","first-page":"2480","DOI":"10.1158\/0008-5472.CAN-12-3542","article-title":"Chemotherapy alters monocyte differentiation to favor generation of cancer-supporting M2 macrophages in the tumor microenvironment","volume":"73","author":"Dijkgraaf","year":"2013","journal-title":"Cancer Res"},{"key":"10.1016\/j.drup.2021.100778_bib0395","doi-asserted-by":"crossref","first-page":"6209","DOI":"10.1021\/jm9008339","article-title":"Optimization of the Antitumor Efficacy of a Synthetic Mitochondrial Toxin by Increasing the Residence Time in the Cytosol","volume":"52","author":"Dilda","year":"2009","journal-title":"J Med Chem"},{"key":"10.1016\/j.drup.2021.100778_bib0400","doi-asserted-by":"crossref","first-page":"4334","DOI":"10.2174\/1381612825666190112164211","article-title":"Potential of Natural-Based Anticancer Compounds for P-Glycoprotein Inhibition","volume":"24","author":"Dinic","year":"2018","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.drup.2021.100778_bib0405","first-page":"503","article-title":"Collateral sensitivity to cisplatin in KB-8-5-11 drug-resistant cancer cells","volume":"34","author":"Doherty","year":"2014","journal-title":"Anticancer Res"},{"key":"10.1016\/j.drup.2021.100778_bib0410","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.bbagen.2018.09.019","article-title":"ABC transporters as cancer drivers: Potential functions in cancer development","volume":"1863","author":"Domenichini","year":"2019","journal-title":"Biochim Biophys Acta Gen Subj"},{"key":"10.1016\/j.drup.2021.100778_bib0415","doi-asserted-by":"crossref","first-page":"2821","DOI":"10.1016\/j.bmcl.2016.04.064","article-title":"Identification of selenocompounds with promising properties to reverse cancer multidrug resistance","volume":"26","author":"Dominguez-Alvarez","year":"2016","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.drup.2021.100778_bib0420","doi-asserted-by":"crossref","first-page":"4382","DOI":"10.1039\/C7DT00439G","article-title":"Comparative solution equilibrium studies of antitumor ruthenium(eta(6)-p-cymene) and rhodium(eta(5)-C5Me5) complexes of 8-hydroxyquinolines","volume":"46","author":"Domotor","year":"2017","journal-title":"Dalton Trans"},{"key":"10.1016\/j.drup.2021.100778_bib0425","doi-asserted-by":"crossref","first-page":"15665","DOI":"10.1073\/pnas.95.26.15665","article-title":"A multidrug resistance transporter from human MCF-7 breast cancer cells","volume":"95","author":"Doyle","year":"1998","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.drup.2021.100778_bib0430","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1200\/JCO.2008.19.3235","article-title":"Phase II study of picoplatin as second-line therapy for patients with small-cell lung cancer","volume":"27","author":"Eckardt","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.drup.2021.100778_bib0435","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1158\/1078-0432.CCR-07-4525","article-title":"Prediction of broad spectrum resistance of tumors towards anticancer drugs","volume":"14","author":"Efferth","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.drup.2021.100778_bib0440","first-page":"138","article-title":"Complete resolution of malignant ascites in stage IV breast cancer by peritoneal drainage and innovative chemoimmunotherapy: A case report","volume":"21","author":"Elliott","year":"2006","journal-title":"Cancer Biother Radiopharm"},{"key":"10.1016\/j.drup.2021.100778_bib0445","first-page":"469","article-title":"Preliminary Evaluation of Platinum Transferrin (Mptc-63) as a Potential Nontoxic Treatment for Breast-Cancer","volume":"12","author":"Elliott","year":"1988","journal-title":"Cancer Detect Prev"},{"key":"10.1016\/j.drup.2021.100778_bib0450","doi-asserted-by":"crossref","DOI":"10.1002\/aoc.5437","article-title":"Metformin Containing Nickel (II) Complexes: Synthesis, Structural Characterization, Binding and Kinetic Interactions with BSA, Antibacterial and in-vitro Cytotoxicity Studies","volume":"34","author":"Elshami","year":"2020","journal-title":"Appl Organomet Chem"},{"key":"10.1016\/j.drup.2021.100778_bib0455","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1021\/acs.chemrev.8b00396","article-title":"Metal Drugs and the Anticancer Immune Response","volume":"119","author":"Englinger","year":"2019","journal-title":"Chem Rev"},{"key":"10.1016\/j.drup.2021.100778_bib0460","doi-asserted-by":"crossref","first-page":"75","DOI":"10.2174\/0929867324666170330091438","article-title":"Gold - Old Drug with New Potentials","volume":"25","author":"Faa","year":"2018","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.drup.2021.100778_bib0465","doi-asserted-by":"crossref","DOI":"10.1042\/BSR20190378","article-title":"Polynuclear ruthenium organometallic compounds induce DNA damage in human cells identified by the nucleotide excision repair factor XPC","volume":"39","author":"Fast","year":"2019","journal-title":"Biosci Rep"},{"key":"10.1016\/j.drup.2021.100778_bib0470","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.drup.2015.11.003","article-title":"Mechanisms of cisplatin resistance and targeting of cancer stem cells: Adding glycosylation to the equation","volume":"24","author":"Ferreira","year":"2016","journal-title":"Drug Resist Updat"},{"key":"10.1016\/j.drup.2021.100778_bib0475","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1038\/s41568-018-0048-x","article-title":"Nutrient scavenging in cancer","volume":"18","author":"Finicle","year":"2018","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.drup.2021.100778_bib0480","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1039\/c3mt00278k","article-title":"Gallium phosphinoarylbisthiolato complexes counteract drug resistance of cancer cells","volume":"6","author":"Fischer-Fodor","year":"2014","journal-title":"Metallomics"},{"key":"10.1016\/j.drup.2021.100778_bib0485","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.drup.2016.03.001","article-title":"ABC transporters as mediators of drug resistance and contributors to cancer cell biology","volume":"26","author":"Fletcher","year":"2016","journal-title":"Drug Resist Updat"},{"key":"10.1016\/j.drup.2021.100778_bib0490","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/s10637-016-0337-8","article-title":"Molecular mode of action of NKP-1339 - a clinically investigated ruthenium-based drug - involves ER- and ROS-related effects in colon carcinoma cell lines","volume":"34","author":"Flocke","year":"2016","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.drup.2021.100778_bib0495","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.jorganchem.2013.09.004","article-title":"Synthesis, characterization and cytotoxicity of cyclopentadienyl ruthenium (II) complexes containing carbohydrate-derived ligands","volume":"760","author":"Florindo","year":"2014","journal-title":"J Organometal Chem"},{"key":"10.1016\/j.drup.2021.100778_bib0500","doi-asserted-by":"crossref","first-page":"11926","DOI":"10.1039\/C6DT01571A","article-title":"New [(\u03b7 5-C 5 H 5) Ru (N\u2013N)(PPh 3)][PF 6] compounds: colon anticancer activity and GLUT-mediated cellular uptake of carbohydrate-appended complexes","volume":"45","author":"Florindo","year":"2016","journal-title":"Dalton Trans"},{"key":"10.1016\/j.drup.2021.100778_bib0505","doi-asserted-by":"crossref","first-page":"4339","DOI":"10.1021\/acs.jmedchem.5b00403","article-title":"Cyclopentadienyl\u2013ruthenium (II) and iron (II) organometallic compounds with carbohydrate derivative ligands as good colorectal anticancer agents","volume":"58","author":"Florindo","year":"2015","journal-title":"J Med Chem"},{"key":"10.1016\/j.drup.2021.100778_bib0510","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1016\/S0006-2952(02)00983-8","article-title":"JM216-, JM118-, and cisplatin-induced cytotoxicity in relation to platinum-DNA adduct formation, glutathione levels and p53 status in human tumour cell lines with different sensitivities to cisplatin","volume":"63","author":"Fokkema","year":"2002","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.drup.2021.100778_bib0515","doi-asserted-by":"crossref","first-page":"188338","DOI":"10.1016\/j.bbcan.2020.188338","article-title":"The emerging role of paraptosis in tumor cell biology: Perspectives for cancer prevention and therapy with natural compounds","volume":"1873","author":"Fontana","year":"2020","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"10.1016\/j.drup.2021.100778_bib0520","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1002\/ijc.2910520421","article-title":"Cytotoxicity of a transferrin-adriamycin conjugate to anthracycline-resistant cells","volume":"52","author":"Fritzer","year":"1992","journal-title":"Int J Cancer"},{"key":"10.1016\/j.drup.2021.100778_bib0525","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/0006-2952(95)02225-2","article-title":"Cytotoxic effects of a doxorubicin-transferrin conjugate in multidrug-resistant KB cells","volume":"51","author":"Fritzer","year":"1996","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.drup.2021.100778_bib0530","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1124\/jpet.105.089342","article-title":"Ruthenium (II)-derived organometallic compounds induce cytostatic and cytotoxic effects on mammalian cancer cell lines through p53-dependent and p53-independent mechanisms","volume":"315","author":"Gaiddon","year":"2005","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.drup.2021.100778_bib0535","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/j.bmcl.2017.01.033","article-title":"Selenoesters and selenoanhydrides as novel multidrug resistance reversing agents: A confirmation study in a colon cancer MDR cell line","volume":"27","author":"Gajdacs","year":"2017","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.drup.2021.100778_bib0540","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.freeradbiomed.2017.01.004","article-title":"Reactive oxygen species and cancer paradox: To promote or to suppress?","volume":"104","author":"Galadari","year":"2017","journal-title":"Free Radic Biol Med"},{"key":"10.1016\/j.drup.2021.100778_bib0545","doi-asserted-by":"crossref","first-page":"5307","DOI":"10.1039\/c2dt11781a","article-title":"Synthesis and characterization of azolate gold(I) phosphane complexes as thioredoxin reductase inhibiting antitumor agents","volume":"41","author":"Galassi","year":"2012","journal-title":"Dalton Trans"},{"key":"10.1016\/j.drup.2021.100778_bib0550","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/nri.2016.107","article-title":"Immunogenic cell death in cancer and infectious disease","volume":"17","author":"Galluzzi","year":"2017","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.drup.2021.100778_bib0555","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.bcp.2009.07.023","article-title":"Cancer cell death induced by phosphine gold(I) compounds targeting thioredoxin reductase","volume":"79","author":"Gandin","year":"2010","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.drup.2021.100778_bib0560","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.freeradbiomed.2018.05.001","article-title":"Organic selenium compounds as potential chemotherapeutic agents for improved cancer treatment","volume":"127","author":"Gandin","year":"2018","journal-title":"Free Radic Biol Med"},{"key":"10.1016\/j.drup.2021.100778_bib0565","doi-asserted-by":"crossref","first-page":"e11253","DOI":"10.1371\/journal.pone.0011253","article-title":"Targeting mitochondrial cell death pathway to overcome drug resistance with a newly developed iron chelate","volume":"5","author":"Ganguly","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.drup.2021.100778_bib0570","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s10534-011-9493-7","article-title":"Iron N-(2-hydroxy acetophenone) glycinate (FeNG), a non-toxic glutathione depletor circumvents doxorubicin resistance in Ehrlich ascites carcinoma cells in vivo","volume":"25","author":"Ganguly","year":"2012","journal-title":"Biometals"},{"key":"10.1016\/j.drup.2021.100778_bib0575","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.jconrel.2008.07.017","article-title":"Cellular accumulation and cytotoxicity of macromolecular platinum complexes in cisplatin-resistant tumor cells","volume":"131","author":"Garmann","year":"2008","journal-title":"J Control Release"},{"key":"10.1016\/j.drup.2021.100778_bib0580","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1006\/geno.1996.0554","article-title":"Human thioredoxin reductase gene localization to chromosomal position 12q23-q24.1 and mRNA distribution in human tissue","volume":"37","author":"Gasdaska","year":"1996","journal-title":"Genomics"},{"key":"10.1016\/j.drup.2021.100778_bib0585","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1007\/s00018-003-4024-5","article-title":"Gene expression profiles in the cellular response to a multinuclear platinum complexe","volume":"61","author":"Gatti","year":"2004","journal-title":"Cell Mol Life Sci"},{"key":"10.1016\/j.drup.2021.100778_bib0590","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1038\/sj.cdd.4401109","article-title":"Apoptosis and growth arrest induced by platinum compounds in U2-OS cells reflect a specific DNA damage recognition associated with a different p53-mediated response","volume":"9","author":"Gatti","year":"2002","journal-title":"Cell Death Diff"},{"key":"10.1016\/j.drup.2021.100778_bib0595","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/j.ejps.2013.05.002","article-title":"A novel manganese complex, Mn-(II) N-(2-hydroxy acetophenone) glycinate overcomes multidrug-resistance in cancer","volume":"49","author":"Ghosh","year":"2013","journal-title":"Eur J Pharm Sci"},{"key":"10.1016\/j.drup.2021.100778_bib0600","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/s11010-012-1232-z","article-title":"The molecular interaction of a copper chelate with human P-glycoprotein","volume":"364","author":"Ghosh","year":"2012","journal-title":"Mol Cell Biochem"},{"key":"10.1016\/j.drup.2021.100778_bib0605","doi-asserted-by":"crossref","first-page":"10873","DOI":"10.1039\/c1dt10501a","article-title":"An in vitro and in vivo study of a novel zinc complex, zinc N-(2-hydroxyacetophenone)glycinate to overcome multidrug resistance in cancer","volume":"40","author":"Ghosh","year":"2011","journal-title":"Dalton Trans"},{"key":"10.1016\/j.drup.2021.100778_bib0610","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.jinorgbio.2018.11.008","article-title":"Multi-action Pt(IV) anticancer agents; do we understand how they work?","volume":"191","author":"Gibson","year":"2019","journal-title":"J Inorg Biochem"},{"key":"10.1016\/j.drup.2021.100778_bib0615","doi-asserted-by":"crossref","DOI":"10.3390\/nu12051500","article-title":"Genetic and Physiological Factors Affecting Human Milk Production and Composition","volume":"12","author":"Golan","year":"2020","journal-title":"Nutrients"},{"key":"10.1016\/j.drup.2021.100778_bib0620","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1039\/C7MT00162B","article-title":"The role of the zinc transporter SLC30A2\/ZnT2 in transient neonatal zinc deficiency","volume":"9","author":"Golan","year":"2017","journal-title":"Metallomics"},{"key":"10.1016\/j.drup.2021.100778_bib0625","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.drup.2012.07.002","article-title":"Antifolates in cancer therapy: Structure, activity and mechanisms of drug resistance","volume":"15","author":"Gonen","year":"2012","journal-title":"Drug Resist Updat"},{"key":"10.1016\/j.drup.2021.100778_bib0630","doi-asserted-by":"crossref","first-page":"37706","DOI":"10.1039\/C7RA06514K","article-title":"Water soluble Ru(II)-arene complexes of the antidiabetic drug metformin: DNA and protein binding, molecular docking, cytotoxicity and apoptosis-inducing activity","volume":"7","author":"Gopalakrishnan","year":"2017","journal-title":"RSC Adv"},{"key":"10.1016\/j.drup.2021.100778_bib0635","first-page":"18","article-title":"Defeating drug resistance in cancer","volume":"6","author":"Gottesman","year":"2006","journal-title":"Discov Med"},{"key":"10.1016\/j.drup.2021.100778_bib0640","doi-asserted-by":"crossref","first-page":"7449","DOI":"10.1038\/sj.onc.1208047","article-title":"Oxaliplatin-induced mitochondrial apoptotic response of colon carcinoma cells does not require nuclear DNA","volume":"23","author":"Gourdier","year":"2004","journal-title":"Oncogene"},{"key":"10.1016\/j.drup.2021.100778_bib0645","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.cell.2005.05.019","article-title":"Apoptotic pathways: ten minutes to dead","volume":"121","author":"Green","year":"2005","journal-title":"Cell"},{"key":"10.1016\/j.drup.2021.100778_bib0650","doi-asserted-by":"crossref","first-page":"5183","DOI":"10.1039\/C8SC01142G","article-title":"Oncosis-inducing cyclometalated iridium(III) complexes","volume":"9","author":"Guan","year":"2018","journal-title":"Chem Sci"},{"key":"10.1016\/j.drup.2021.100778_bib0655","doi-asserted-by":"crossref","first-page":"15457","DOI":"10.1039\/c3dt51991k","article-title":"Synthesis, molecular structure, computational study and in vitro anticancer activity of dinuclear thiolato-bridged pentamethylcyclopentadienyl Rh(III) and Ir(III) complexes","volume":"42","author":"Gupta","year":"2013","journal-title":"Dalton Trans"},{"key":"10.1016\/j.drup.2021.100778_bib0660","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/S0076-6879(81)77029-0","article-title":"Glutathione S-transferases (rat and human)","volume":"77","author":"Habig","year":"1981","journal-title":"Methods Enzymol"},{"key":"10.1016\/j.drup.2021.100778_bib0665","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1089\/ars.2019.7854","article-title":"High Copper Complex Stability and Slow Reduction Kinetics as Key Parameters for Improved Activity, Paraptosis Induction, and Impact on Drug-Resistant Cells of Anticancer Thiosemicarbazones","volume":"33","author":"Hager","year":"2020","journal-title":"Antioxid Redox Signal"},{"key":"10.1016\/j.drup.2021.100778_bib0670","doi-asserted-by":"crossref","first-page":"5878","DOI":"10.1021\/jm2006047","article-title":"Synthesis and structure-activity evaluation of isatin-beta-thiosemicarbazones with improved selective activity toward multidrug-resistant cells expressing P-glycoprotein","volume":"54","author":"Hall","year":"2011","journal-title":"J Med Chem"},{"key":"10.1016\/j.drup.2021.100778_bib0675","doi-asserted-by":"crossref","first-page":"3191","DOI":"10.1021\/jm800861c","article-title":"Synthesis, activity, and pharmacophore development for isatin-beta-thiosemicarbazones with selective activity toward multidrug-resistant cells","volume":"52","author":"Hall","year":"2009","journal-title":"J Med Chem"},{"key":"10.1016\/j.drup.2021.100778_bib0680","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1517\/17425255.2013.815724","article-title":"Picoplatin pharmacokinetics and chemotherapy of non-small cell lung cancer","volume":"9","author":"Hamilton","year":"2013","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1016\/j.drup.2021.100778_bib0685","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.jconrel.2018.01.019","article-title":"Intracellular glutathione-depleting polymeric micelles for cisplatin prodrug delivery to overcome cisplatin resistance of cancers","volume":"273","author":"Han","year":"2018","journal-title":"J Control Release"},{"key":"10.1016\/j.drup.2021.100778_bib0690","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.drup.2021.100778_bib0695","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.jinorgbio.2016.06.025","article-title":"Anticancer activity of Ru- and Os(arene) compounds of a maleimide-functionalized bioactive pyridinecarbothioamide ligand","volume":"165","author":"Hanif","year":"2016","journal-title":"J Inorg Biochem"},{"key":"10.1016\/j.drup.2021.100778_bib0700","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1039\/C1CC14713G","article-title":"Maleimide-functionalised organoruthenium anticancer agents and their binding to thiol-containing biomolecules","volume":"48","author":"Hanif","year":"2012","journal-title":"Chem Comm"},{"key":"10.1016\/j.drup.2021.100778_bib0705","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1096\/fj.02-0541com","article-title":"Characterization of a novel metabolic strategy used by drug-resistant tumor cells","volume":"16","author":"Harper","year":"2002","journal-title":"FASEB J"},{"key":"10.1016\/j.drup.2021.100778_bib0710","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1124\/mol.105.018762","article-title":"Biological consequences of trinuclear platinum complexes: comparison of [[trans-PtCl(NH3)2]2mu-(trans-Pt(NH3)2(H2N(CH2)6-NH2)2)]4+ (BBR 3464) with its noncovalent congeners","volume":"69","author":"Harris","year":"2006","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.drup.2021.100778_bib0715","doi-asserted-by":"crossref","first-page":"6005","DOI":"10.21873\/anticanres.11189","article-title":"Anticancer Effects of a New Aminosugar-conjugated Platinum Complex Agent Against Cisplatin-resistant Gastric Cancer","volume":"36","author":"Hayashi","year":"2016","journal-title":"Anticancer Res"},{"key":"10.1016\/j.drup.2021.100778_bib0720","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1146\/annurev.pharmtox.45.120403.095857","article-title":"GLUTATHIONE TRANSFERASES","volume":"45","author":"Hayes","year":"2005","journal-title":"Ann Rev Pharmacol Toxicol"},{"key":"10.1016\/j.drup.2021.100778_bib0725","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.drup.2019.04.001","article-title":"YY1 regulates cancer cell immune resistance by modulating PD-L1 expression","volume":"43","author":"Hays","year":"2019","journal-title":"Drug Resist Updat"},{"key":"10.1016\/j.drup.2021.100778_bib0730","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1007\/s00280-004-0932-9","article-title":"Investigation of the role of Bax, p21\/Waf1 and p53 as determinants of cellular responses in HCT116 colorectal cancer cells exposed to the novel cytotoxic ruthenium(II) organometallic agent, RM175","volume":"55","author":"Hayward","year":"2005","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.drup.2021.100778_bib0735","doi-asserted-by":"crossref","first-page":"6942","DOI":"10.1039\/C8DT00783G","article-title":"Cyclometalated iridium(iii) complexes induce mitochondria-derived paraptotic cell death and inhibit tumor growth in vivo","volume":"47","author":"He","year":"2018","journal-title":"Dalton Trans"},{"key":"10.1016\/j.drup.2021.100778_bib0740","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1016\/j.bcp.2007.03.002","article-title":"Multidrug-resistant cancer cells are preferential targets of the new antineoplastic lanthanum compound KP772 (FFC24)","volume":"73","author":"Heffeter","year":"2007","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.drup.2021.100778_bib0745","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.bcp.2005.11.009","article-title":"Anticancer activity of the lanthanum compound [tris(1,10-phenanthroline)lanthanum(III)]trithiocyanate (KP772; FFC24)","volume":"71","author":"Heffeter","year":"2006","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.drup.2021.100778_bib0750","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.drup.2008.02.002","article-title":"Resistance against novel anticancer metal compounds: differences and similarities","volume":"11","author":"Heffeter","year":"2008","journal-title":"Drug Resist Updat"},{"key":"10.1016\/j.drup.2021.100778_bib0755","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1089\/ars.2017.7487","article-title":"Anticancer Thiosemicarbazones: Chemical Properties, Interaction with Iron Metabolism, and Resistance Development","volume":"30","author":"Heffeter","year":"2019","journal-title":"Antioxid Redox Signal"},{"key":"10.1016\/j.drup.2021.100778_bib0760","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1124\/jpet.104.073395","article-title":"Intrinsic and acquired forms of resistance against the anticancer ruthenium compound KP1019 [indazolium trans-[tetrachlorobis(1H-indazole)ruthenate (III)] (FFC14A)","volume":"312","author":"Heffeter","year":"2005","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.drup.2021.100778_bib0765","doi-asserted-by":"crossref","first-page":"595","DOI":"10.2174\/156800909789056962","article-title":"Ribonucleotide reductase as one important target of [Tris(1,10-phenanthroline)lanthanum(III)] trithiocyanate (KP772)","volume":"9","author":"Heffeter","year":"2009","journal-title":"Curr Cancer Drug Targets"},{"key":"10.1016\/j.drup.2021.100778_bib0770","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.bcp.2012.04.010","article-title":"Interaction of the EGFR inhibitors gefitinib, vandetanib, pelitinib and neratinib with the ABCG2 multidrug transporter: implications for the emergence and reversal of cancer drug resistance","volume":"84","author":"Hegedus","year":"2012","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.drup.2021.100778_bib0775","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1097\/01.cad.0000215054.62942.7f","article-title":"Phase II study of BBR 3464 as treatment in patients with sensitive or refractory small cell lung cancer","volume":"17","author":"Hensing","year":"2006","journal-title":"Anti-Cancer Drug"},{"key":"10.1016\/j.drup.2021.100778_bib0780","first-page":"997","article-title":"Characterization of mitochondria in cisplatin-resistant human ovarian carcinoma cells","volume":"16","author":"Hirama","year":"2006","journal-title":"Oncol Rep"},{"key":"10.1016\/j.drup.2021.100778_bib0785","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.jinorgbio.2017.04.003","article-title":"Rational design of dicarboxylato platinum(II) complexes with purine-mimetic ligands as novel anticancer agents","volume":"172","author":"Hoffmann","year":"2017","journal-title":"J Inorg Biochem"},{"key":"10.1016\/j.drup.2021.100778_bib0790","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1016\/S0959-8049(00)00192-1","article-title":"Mechanisms of drug resistance to the platinum complex ZD0473 in ovarian cancer cell lines","volume":"36","author":"Holford","year":"2000","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.drup.2021.100778_bib0795","first-page":"1","article-title":"Chemical, biochemical and pharmacological activity of the novel sterically hindered platinum co-ordination complex, cis-[amminedichloro(2-methylpyridine)] platinum(II) (AMD473)","volume":"13","author":"Holford","year":"1998","journal-title":"Anticancer Drug Des"},{"key":"10.1016\/j.drup.2021.100778_bib0800","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1038\/bjc.1998.59","article-title":"In vitro circumvention of cisplatin resistance by the novel sterically hindered platinum complex AMD473","volume":"77","author":"Holford","year":"1998","journal-title":"Br J Cancer"},{"key":"10.1016\/j.drup.2021.100778_bib0805","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.addr.2018.07.011","article-title":"Harnessing albumin as a carrier for cancer therapies","volume":"130","author":"Hoogenboezem","year":"2018","journal-title":"Adv Drug Deliver Rev"},{"key":"10.1016\/j.drup.2021.100778_bib0810","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.ygyno.2005.11.016","article-title":"Platinum(IV) complex with adamantylamine overcomes intrinsic resistance to cisplatin in ovarian cancer cells","volume":"102","author":"Horvath","year":"2006","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.drup.2021.100778_bib0815","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1124\/mol.109.063172","article-title":"Copper transporters and the cellular pharmacology of the platinum-containing cancer drugs","volume":"77","author":"Howell","year":"2010","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.drup.2021.100778_bib0820","doi-asserted-by":"crossref","first-page":"686","DOI":"10.2174\/1871520616666151120122611","article-title":"Metal Containing Cytostatics and Their Interaction with Cellular Thiol Compounds Causing Chemoresistance","volume":"16","author":"Hrabeta","year":"2016","journal-title":"Anti Cancer Agent Med Chem"},{"key":"10.1016\/j.drup.2021.100778_bib0825","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/0006-2952(93)90399-H","article-title":"The role of metallothionein, glutathione, glutathione S-transferases and DNA repair in resistance to platinum drugs in a series of L1210 cell lines made resistant to anticancer platinum agents","volume":"45","author":"Hrubisko","year":"1993","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.drup.2021.100778_bib0830","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.canlet.2012.03.019","article-title":"Acquisition of an enhanced aggressive phenotype in human lung cancer cells selected by suboptimal doses of cisplatin following cell deattachment and reattachment","volume":"321","author":"Hsieh","year":"2012","journal-title":"Cancer Lett"},{"key":"10.1016\/j.drup.2021.100778_bib0835","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.drup.2018.03.001","article-title":"How the Warburg effect supports aggressiveness and drug resistance of cancer cells?","volume":"38","author":"Icard","year":"2018","journal-title":"Drug Resist Updat"},{"key":"10.1016\/j.drup.2021.100778_bib0840","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10254-002-0001-x","article-title":"Tumour-inhibiting platinum complexes-state of the art and future perspectives","volume":"146","author":"Jakupec","year":"2003","journal-title":"Rev Physiol Biochem Pharmacol"},{"key":"10.1016\/j.drup.2021.100778_bib0845","doi-asserted-by":"crossref","first-page":"9588","DOI":"10.1074\/jbc.M114.631283","article-title":"Di-2-pyridylketone 4,4-dimethyl-3-thiosemicarbazone (Dp44mT) overcomes multidrug resistance by a novel mechanism involving the hijacking of lysosomal P-glycoprotein (Pgp)","volume":"290","author":"Jansson","year":"2015","journal-title":"J Biol Chem"},{"key":"10.1016\/j.drup.2021.100778_bib0850","doi-asserted-by":"crossref","first-page":"6507","DOI":"10.1021\/acs.inorgchem.9b00708","article-title":"Targeting Energy Metabolism by a Platinum(IV) Prodrug as an Alternative Pathway for Cancer Suppression","volume":"58","author":"Jin","year":"2019","journal-title":"Inorg Chem"},{"key":"10.1016\/j.drup.2021.100778_bib0855","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1016\/j.ejca.2004.04.032","article-title":"Phase II studies of BBR3464, a novel tri-nuclear platinum complex, in patients with gastric or gastro-oesopliageal adenocarcinoma","volume":"40","author":"Jodrell","year":"2004","journal-title":"Eur J Can"},{"key":"10.1016\/j.drup.2021.100778_bib0860","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1006\/excr.1996.0211","article-title":"Cross-resistance, cisplatin accumulation, and platinum-DNA adduct formation and removal in cisplatin-sensitive and -resistant human hepatoma cell lines","volume":"226","author":"Johnson","year":"1996","journal-title":"Exp Cell Res"},{"key":"10.1016\/j.drup.2021.100778_bib0865","doi-asserted-by":"crossref","first-page":"5675","DOI":"10.1021\/nn401905g","article-title":"Nanoparticle Encapsulation of Mitaplatin and the Effect Thereof on In Vivo Properties","volume":"7","author":"Johnstone","year":"2013","journal-title":"ACS Nano"},{"key":"10.1016\/j.drup.2021.100778_bib0870","doi-asserted-by":"crossref","first-page":"3436","DOI":"10.1021\/acs.chemrev.5b00597","article-title":"The Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) Prodrugs","volume":"116","author":"Johnstone","year":"2016","journal-title":"Chem Rev"},{"key":"10.1016\/j.drup.2021.100778_bib0875","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1097\/00007691-200306000-00014","article-title":"Doxorubicin-resistant, MRP1-expressing U-1285 cells are sensitive to idarubicin","volume":"25","author":"Jonsson-Videsater","year":"2003","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.drup.2021.100778_bib0880","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.drup.2015.05.002","article-title":"Fighting cancer drug resistance: Opportunities and challenges for mutation-specific EGFR inhibitors","volume":"20","author":"Juchum","year":"2015","journal-title":"Drug Resist Updat"},{"key":"10.1016\/j.drup.2021.100778_bib0885","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1089\/ars.2010.3663","article-title":"Anticancer activity of metal complexes: involvement of redox processes","volume":"15","author":"Jungwirth","year":"2011","journal-title":"Antioxid Redox Signal"},{"key":"10.1016\/j.drup.2021.100778_bib0890","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1124\/mol.111.077321","article-title":"Anticancer activity of methyl-substituted oxaliplatin analogs","volume":"81","author":"Jungwirth","year":"2012","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.drup.2021.100778_bib0895","first-page":"617","article-title":"Dichloroacetate and cancer: new home for an orphan drug?","volume":"1846","author":"Kankotia","year":"2014","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.drup.2021.100778_bib0900","doi-asserted-by":"crossref","first-page":"12163","DOI":"10.1021\/bi034149+","article-title":"A mechanism for P-glycoprotein-mediated apoptosis as revealed by verapamil hypersensitivity","volume":"42","author":"Karwatsky","year":"2003","journal-title":"Biochem"},{"key":"10.1016\/j.drup.2021.100778_bib0905","doi-asserted-by":"crossref","first-page":"5546","DOI":"10.1093\/nar\/gkh896","article-title":"Differential recognition by the tumor suppressor protein p53 of DNA modified by the novel antitumor trinuclear platinum drug BBR3464 and cisplatin","volume":"32","author":"Kasparkova","year":"2004","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.drup.2021.100778_bib0910","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1007\/s10534-017-0037-7","article-title":"Iron metabolism and drug resistance in cancer","volume":"30","author":"Kazan","year":"2017","journal-title":"Biometals"},{"key":"10.1016\/j.drup.2021.100778_bib0915","first-page":"83","article-title":"Microtiter plate technique for the measurement of glutathione in fresh and cryopreserved lymphoblasts using the enzyme recycling method","volume":"28","author":"Kearns","year":"1999","journal-title":"Methods Mol Med"},{"key":"10.1016\/j.drup.2021.100778_bib0920","first-page":"2581","article-title":"Preclinical antitumor evaluation of bis-acetato-ammine-dichloro-cyclohexylamine platinum(IV): an orally active platinum drug","volume":"53","author":"Kelland","year":"1993","journal-title":"Cancer Res"},{"key":"10.1016\/j.drup.2021.100778_bib0925","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1021\/acs.chemrev.8b00271","article-title":"Toward Multi-Targeted Platinum and Ruthenium Drugs-A New Paradigm in Cancer Drug Treatment Regimens?","volume":"119","author":"Kenny","year":"2019","journal-title":"Chem Rev"},{"key":"10.1016\/j.drup.2021.100778_bib0930","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.bbrc.2007.01.117","article-title":"Reversal of multidrug resistance by 4-chloro-N-(3-((E)-3-(4-hydroxy-3-methoxyphenyl)acryloyl)phenyl)benzamide through the reversible inhibition of P-glycoprotein","volume":"355","author":"Kim","year":"2007","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.drup.2021.100778_bib0935","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.3390\/cancers13102493","article-title":"Organoruthenium Complexes with Benzo-Fused Pyrithiones Overcome Platinum Resistance in Ovarian Cancer Cells","volume":"13","author":"Kladnik","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.drup.2021.100778_bib0940","doi-asserted-by":"crossref","first-page":"14169","DOI":"10.1002\/chem.201903109","article-title":"Towards Identification of Essential Structural Elements of Organoruthenium(II)-Pyrithionato Complexes for Anticancer Activity","volume":"25","author":"Kladnik","year":"2019","journal-title":"Chem Eur J"},{"key":"10.1016\/j.drup.2021.100778_bib0945","doi-asserted-by":"crossref","first-page":"14302","DOI":"10.1021\/jacs.7b08640","article-title":"In vitro anticancer activity and in vivo biodistribution of rhenium (I) tricarbonyl aqua complexes","volume":"139","author":"Knopf","year":"2017","journal-title":"J AmChem Soc"},{"key":"10.1016\/j.drup.2021.100778_bib0950","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.drup.2019.07.004","article-title":"Immune checkpoint inhibitor combinations: Current efforts and important aspects for success","volume":"45","author":"Kon","year":"2019","journal-title":"Drug Resist Updat"},{"key":"10.1016\/j.drup.2021.100778_bib0955","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1039\/C7MD00545H","article-title":"Resistance-breaking profiling and gene expression analysis on an organometallic Re(I)-phenanthridine complex reveal parallel activation of two apoptotic pathways","volume":"9","author":"Konig","year":"2018","journal-title":"MedChemComm"},{"key":"10.1016\/j.drup.2021.100778_bib0960","doi-asserted-by":"crossref","first-page":"3895","DOI":"10.1021\/acs.inorgchem.8b03552","article-title":"Combinatorial Synthesis to Identify a Potent, Necrosis-Inducing Rhenium Anticancer Agent","volume":"58","author":"Konkankit","year":"2019","journal-title":"Inorg Chem"},{"key":"10.1016\/j.drup.2021.100778_bib0965","first-page":"3248","article-title":"Increased expression of DNA topoisomerase I gene and collateral sensitivity to camptothecin in human cisplatin-resistant bladder cancer cells","volume":"54","author":"Kotoh","year":"1994","journal-title":"Cancer Res"},{"key":"10.1016\/j.drup.2021.100778_bib0970","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.jconrel.2008.05.010","article-title":"Albumin as a drug carrier: design of prodrugs, drug conjugates and nanoparticles","volume":"132","author":"Kratz","year":"2008","journal-title":"J Control Release"},{"key":"10.1016\/j.drup.2021.100778_bib0975","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1158\/1535-7163.MCT-13-0065","article-title":"Synergistic anticancer activity of arsenic trioxide with erlotinib is based on inhibition of EGFR-mediated DNA double-strand break repair","volume":"12","author":"Kryeziu","year":"2013","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.drup.2021.100778_bib0980","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s10555-007-9045-3","article-title":"The roles of copper transporters in cisplatin resistance","volume":"26","author":"Kuo","year":"2007","journal-title":"Cancer Metastasis Rev"},{"key":"10.1016\/j.drup.2021.100778_bib0985","doi-asserted-by":"crossref","first-page":"6836","DOI":"10.1073\/pnas.111057298","article-title":"The copper transporter CTR1 provides an essential function in mammalian embryonic development","volume":"98","author":"Kuo","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.drup.2021.100778_bib0990","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19051486","article-title":"Modulating Chemosensitivity of Tumors to Platinum-Based Antitumor Drugs by Transcriptional Regulation of Copper Homeostasis","volume":"19","author":"Lai","year":"2018","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.drup.2021.100778_bib0995","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1016\/S0006-2952(97)00599-6","article-title":"Decreased drug accumulation and increased tolerance to DNA damage in tumor cells with a low level of cisplatin resistance","volume":"55","author":"Lanzi","year":"1998","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.drup.2021.100778_bib1000","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1124\/mol.108.052381","article-title":"The role of the mammalian copper transporter 1 in the cellular accumulation of platinum-based drugs","volume":"75","author":"Larson","year":"2009","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.drup.2021.100778_bib1005","doi-asserted-by":"crossref","first-page":"55003","DOI":"10.18632\/oncotarget.18991","article-title":"New perspectives of cobalt tris(bipyridine) system: anti-cancer effect and its collateral sensitivity towards multidrug-resistant (MDR) cancers","volume":"8","author":"Law","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.drup.2021.100778_bib1010","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1097\/00001813-200302000-00012","article-title":"Differential effects of the optical isomers of KR30031 on cardiotoxicity and on multidrug resistance reversal activity","volume":"14","author":"Lee","year":"2003","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.drup.2021.100778_bib1015","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.pharmthera.2016.01.003","article-title":"Paraptosis in the anti-cancer arsenal of natural products","volume":"162","author":"Lee","year":"2016","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.drup.2021.100778_bib1020","doi-asserted-by":"crossref","first-page":"4380","DOI":"10.1074\/jbc.M104728200","article-title":"Biochemical characterization of the human copper transporter Ctr1","volume":"277","author":"Lee","year":"2002","journal-title":"J Biol Chem"},{"key":"10.1016\/j.drup.2021.100778_bib1025","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1002\/cmdc.201800105","article-title":"Development of an Efficient Dual-Action GST-Inhibiting Anticancer Platinum(IV) Prodrug","volume":"13","author":"Lee","year":"2018","journal-title":"ChemMedChem"},{"key":"10.1016\/j.drup.2021.100778_bib1030","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/35085008","article-title":"Four deaths and a funeral: from caspases to alternative mechanisms","volume":"2","author":"Leist","year":"2001","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.drup.2021.100778_bib1035","doi-asserted-by":"crossref","first-page":"100644","DOI":"10.1016\/j.drup.2019.100644","article-title":"Molecular basis and rationale for combining immune checkpoint inhibitors with chemotherapy in non-small cell lung cancer","volume":"46","author":"Leonetti","year":"2019","journal-title":"Drug Resist Updat"},{"key":"10.1016\/j.drup.2021.100778_bib1040","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1021\/cb500528c","article-title":"Underestimated potential of organometallic rhenium complexes as anticancer agents","volume":"9","author":"Leonidova","year":"2014","journal-title":"ACS Chem Biol"},{"key":"10.1016\/j.drup.2021.100778_bib1045","doi-asserted-by":"crossref","first-page":"100704","DOI":"10.1016\/j.drup.2020.100704","article-title":"Nanomedicine to target multidrug resistant tumors","volume":"52","author":"Lepeltier","year":"2020","journal-title":"Drug Resist Updat"},{"key":"10.1016\/j.drup.2021.100778_bib1050","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.tox.2006.07.017","article-title":"Selenium: from cancer prevention to DNA damage","volume":"227","author":"Letavayova","year":"2006","journal-title":"Toxicology"},{"key":"10.1016\/j.drup.2021.100778_bib1055","doi-asserted-by":"crossref","first-page":"6865","DOI":"10.1039\/C7SC02205K","article-title":"Cytotoxic (salen)ruthenium(iii) anticancer complexes exhibit different modes of cell death directed by axial ligands","volume":"8","author":"Li","year":"2017","journal-title":"Chem Sci"},{"key":"10.1016\/j.drup.2021.100778_bib1060","doi-asserted-by":"crossref","first-page":"3548","DOI":"10.18632\/oncotarget.6516","article-title":"Auranofin-mediated inhibition of PI3K\/AKT\/mTOR axis and anticancer activity in non-small cell lung cancer cells","volume":"7","author":"Li","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.drup.2021.100778_bib1065","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.biomaterials.2017.08.021","article-title":"Overcoming resistance to cisplatin by inhibition of glutathione S-transferases (GSTs) with ethacraplatin micelles in vitro and in vivo","volume":"144","author":"Li","year":"2017","journal-title":"Biomaterials"},{"key":"10.1016\/j.drup.2021.100778_bib1070","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.drup.2016.05.001","article-title":"Overcoming ABC transporter-mediated multidrug resistance: Molecular mechanisms and novel therapeutic drug strategies","volume":"27","author":"Li","year":"2016","journal-title":"Drug Resist Update"},{"key":"10.1016\/j.drup.2021.100778_bib1075","first-page":"2425","article-title":"The thioredoxin-thioredoxin reductase system: over-expression in human cancer","volume":"23","author":"Lincoln","year":"2003","journal-title":"Anticancer Res"},{"key":"10.1016\/j.drup.2021.100778_bib1080","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1155\/MBD.1996.243","volume":"3","author":"Lipponer","year":"1996","journal-title":"Met Based Drugs"},{"key":"10.1016\/j.drup.2021.100778_bib1085","doi-asserted-by":"crossref","first-page":"39476","DOI":"10.18632\/oncotarget.17073","article-title":"GLUT1-mediated selective tumor targeting with fluorine containing platinum(II) glycoconjugates","volume":"8","author":"Liu","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.drup.2021.100778_bib1090","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.jinorgbio.2015.02.002","article-title":"Design, synthesis and anticancer activity of diam(m)ine platinum(II) complexes bearing a small-molecular cell apoptosis inducer dichloroacetate","volume":"146","author":"Liu","year":"2015","journal-title":"J Inorg Biochem"},{"key":"10.1016\/j.drup.2021.100778_bib1095","doi-asserted-by":"crossref","first-page":"2464","DOI":"10.1038\/srep02464","article-title":"Two mixed-NH3\/amine platinum (II) anticancer complexes featuring a dichloroacetate moiety in the leaving group","volume":"3","author":"Liu","year":"2013","journal-title":"Sci Rep"},{"key":"10.1016\/j.drup.2021.100778_bib1100","doi-asserted-by":"crossref","first-page":"75206","DOI":"10.18632\/oncotarget.20663","article-title":"Metformin partially reverses the carboplatin-resistance in NSCLC by inhibiting glucose metabolism","volume":"8","author":"Liu","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.drup.2021.100778_bib1105","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1016\/j.addr.2013.08.006","article-title":"Rationally designed nanovehicles to overcome cancer chemoresistance","volume":"65","author":"Livney","year":"2013","journal-title":"Adv Drug Deliver Rev"},{"key":"10.1016\/j.drup.2021.100778_bib1110","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1002\/path.1706","article-title":"Molecular mechanisms of drug resistance","volume":"205","author":"Longley","year":"2005","journal-title":"J Pathol"},{"key":"10.1016\/j.drup.2021.100778_bib1115","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.tox.2019.02.005","article-title":"Mechanisms of soft and hard electrophile toxicities","volume":"418","author":"LoPachin","year":"2019","journal-title":"Toxicology"},{"key":"10.1016\/j.drup.2021.100778_bib1120","doi-asserted-by":"crossref","first-page":"4940","DOI":"10.1021\/acs.jmedchem.5b00455","article-title":"Hypoxia-Sensitive Metal beta-Ketoiminato Complexes Showing Induced Single-Strand DNA Breaks and Cancer Cell Death by Apoptosis","volume":"58","author":"Lord","year":"2015","journal-title":"J Med Chem"},{"key":"10.1016\/j.drup.2021.100778_bib1125","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/nature03098","article-title":"Intrinsic tumour suppression","volume":"432","author":"Lowe","year":"2004","journal-title":"Nature"},{"key":"10.1016\/j.drup.2021.100778_bib1130","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1074\/jbc.R800045200","article-title":"Selenoproteins","volume":"284","author":"Lu","year":"2009","journal-title":"J Biol Chem"},{"key":"10.1016\/j.drup.2021.100778_bib1135","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1038\/s41467-017-01651-9","article-title":"Nano-enabled pancreas cancer immunotherapy using immunogenic cell death and reversing immunosuppression","volume":"8","author":"Lu","year":"2017","journal-title":"Nature Comm"},{"key":"10.1016\/j.drup.2021.100778_bib1140","doi-asserted-by":"crossref","first-page":"736837","DOI":"10.1155\/2012\/736837","article-title":"Glutathione homeostasis and functions: potential targets for medical interventions","volume":"2012","author":"Lushchak","year":"2012","journal-title":"J Amino Acids"},{"key":"10.1016\/j.drup.2021.100778_bib1145","doi-asserted-by":"crossref","first-page":"386","DOI":"10.3389\/fchem.2018.00386","article-title":"Protected and De-protected Platinum(IV) Glycoconjugates With GLUT1 and OCT2-Mediated Selective Cancer Targeting: Demonstrated Enhanced Transporter-Mediated Cytotoxic Properties in vitro and in vivo","volume":"6","author":"Ma","year":"2018","journal-title":"Front Chem"},{"key":"10.1016\/j.drup.2021.100778_bib1150","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.cbi.2005.10.044","article-title":"The role of a novel copper complex in overcoming doxorubicin resistance in Ehrlich ascites carcinoma cells in vivo","volume":"159","author":"Majumder","year":"2006","journal-title":"Chem Biol Interact"},{"key":"10.1016\/j.drup.2021.100778_bib1155","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.canlet.2005.11.030","article-title":"Reversal of drug resistance in P-glycoprotein-expressing T-cell acute lymphoblastic CEM leukemia cells by copper N-(2-hydroxy acetophenone) glycinate and oxalyl bis (N-phenyl) hydroxamic acid","volume":"244","author":"Majumder","year":"2006","journal-title":"Cancer Lett"},{"key":"10.1016\/j.drup.2021.100778_bib1160","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/j.ejmech.2003.08.002","article-title":"Synthesis, characterization and biological properties of a novel copper complex","volume":"38","author":"Majumder","year":"2003","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.drup.2021.100778_bib1165","doi-asserted-by":"crossref","first-page":"148","DOI":"10.2478\/raon-2019-0018","article-title":"Cisplatin and beyond: molecular mechanisms of action and drug resistance development in cancer chemotherapy","volume":"53","author":"Makovec","year":"2019","journal-title":"Radiol Oncol"},{"key":"10.1016\/j.drup.2021.100778_bib1170","doi-asserted-by":"crossref","first-page":"21","DOI":"10.2174\/1568009033333727","article-title":"Mechanisms controlling sensitivity to platinum complexes: role of p53 and DNA mismatch repair","volume":"3","author":"Manic","year":"2003","journal-title":"Curr Cancer Drug Targets"},{"key":"10.1016\/j.drup.2021.100778_bib1175","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1208\/s12248-014-9668-6","article-title":"Role of the breast cancer resistance protein (BCRP\/ABCG2) in drug transport--an update","volume":"17","author":"Mao","year":"2015","journal-title":"AAPS J"},{"key":"10.1016\/j.drup.2021.100778_bib1180","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/j.jinorgbio.2006.07.010","article-title":"Sterically hindered complexes of platinum(II) with planar heterocyclic nitrogen donors. A novel complex with 1-methyl-cytosine has a spectrum of activity different from cisplatin and is able of overcoming acquired cisplatin resistance","volume":"100","author":"Margiotta","year":"2006","journal-title":"J Inorg Biochem"},{"key":"10.1016\/j.drup.2021.100778_bib1185","doi-asserted-by":"crossref","first-page":"407","DOI":"10.3390\/cancers11030407","article-title":"Mechanisms of Anticancer Drug Resistance in Hepatoblastoma","volume":"11","author":"Marin","year":"2019","journal-title":"Cancers"},{"key":"10.1016\/j.drup.2021.100778_bib1190","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.3390\/molecules25071512","article-title":"Binding Kinetics of Ruthenium Pyrithione Chemotherapeutic Candidates to Human Serum Proteins Studied by HPLC-ICP-MS","volume":"25","author":"Markovic","year":"2020","journal-title":"Molecules"},{"key":"10.1016\/j.drup.2021.100778_bib1195","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.bcp.2007.03.025","article-title":"Accumulation, platinum-DNA adduct formation and cytotoxicity of cisplatin, oxaliplatin and satraplatin in sensitive and resistant human osteosarcoma cell lines, characterized by p53 wild-type status","volume":"74","author":"Martelli","year":"2007","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.drup.2021.100778_bib1200","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1158\/1535-7163.MCT-14-0636","article-title":"Tumor-Related Molecular Mechanisms of Oxaliplatin Resistance","volume":"14","author":"Martinez-Balibrea","year":"2015","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.drup.2021.100778_bib1205","doi-asserted-by":"crossref","first-page":"7317","DOI":"10.1021\/jm0601248","article-title":"Synthesis, characterization, and in vitro antitumor properties of tris(hydroxymethyl)phosphine copper(I) complexes containing the new bis(1,2,4-triazol-1-yl)acetate ligand","volume":"49","author":"Marzano","year":"2006","journal-title":"J Med Chem"},{"key":"10.1016\/j.drup.2021.100778_bib1210","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1158\/1535-7163.MCT-08-1072","article-title":"Darinaparsin induces a unique cellular response and is active in an arsenic trioxide-resistant myeloma cell line","volume":"8","author":"Matulis","year":"2009","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.drup.2021.100778_bib1215","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.1039\/C6SC03862J","article-title":"An albumin-based tumor-targeted oxaliplatin prodrug with distinctly improved anticancer activity in vivo","volume":"8","author":"Mayr","year":"2017","journal-title":"Chem Sci"},{"key":"10.1016\/j.drup.2021.100778_bib1220","first-page":"6194","article-title":"Mechanisms of acquired resistance to the orally active platinum-based anticancer drug bis-acetato-ammine-dichloro-cyclohexylamine platinum (i.v.) (JM216) in two human ovarian carcinoma cell lines","volume":"54","author":"Mellish","year":"1994","journal-title":"Cancer Res"},{"key":"10.1016\/j.drup.2021.100778_bib1225","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.radonc.2011.06.003","article-title":"Selection of radioresistant tumor cells and presence of ALDH1 activity in vitro","volume":"99","author":"Mihatsch","year":"2011","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.drup.2021.100778_bib1230","doi-asserted-by":"crossref","first-page":"84556","DOI":"10.18632\/oncotarget.11821","article-title":"Loss of phosphodiesterase 4D mediates acquired triapine resistance via Epac-Rap1-Integrin signaling","volume":"7","author":"Miklos","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.drup.2021.100778_bib1235","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.canlet.2015.02.049","article-title":"Triapine-mediated ABCB1 induction via PKC induces widespread therapy unresponsiveness but is not underlying acquired triapine resistance","volume":"361","author":"Miklos","year":"2015","journal-title":"Cancer Lett"},{"key":"10.1016\/j.drup.2021.100778_bib1240","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1007\/s00280-019-03912-4","article-title":"The thioredoxin system and cancer therapy: a review","volume":"84","author":"Mohammadi","year":"2019","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.drup.2021.100778_bib1245","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.phrs.2016.03.032","article-title":"The water soluble ruthenium(II) organometallic compound [Ru(p-cymene)(bis(3,5 dimethylpyrazol-1-yl)methane)Cl]Cl suppresses triple negative breast cancer growth by inhibiting tumor infiltration of regulatory T cells","volume":"107","author":"Montani","year":"2016","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.drup.2021.100778_bib1250","doi-asserted-by":"crossref","first-page":"4339","DOI":"10.1158\/1078-0432.CCR-06-0001","article-title":"Overcoming drug-resistant cancer by a newly developed copper chelate through host-protective cytokine-mediated apoptosis","volume":"12","author":"Mookerjee","year":"2006","journal-title":"Clinical Cancer Research"},{"key":"10.1016\/j.drup.2021.100778_bib1255","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1186\/1471-2407-6-267","article-title":"A novel copper complex induces ROS generation in doxorubicin resistant Ehrlich ascitis carcinoma cells and increases activity of antioxidant enzymes in vital organs in vivo","volume":"6","author":"Mookerjee","year":"2006","journal-title":"BMC Cancer"},{"key":"10.1016\/j.drup.2021.100778_bib1260","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.jinorgbio.2013.01.011","article-title":"Biological activity and cellular uptake of [Ru(eta5-C5H5)(PPh3)(Me2bpy)][CF3SO3] complex","volume":"122","author":"Morais","year":"2013","journal-title":"J Inorg Biochem"},{"key":"10.1016\/j.drup.2021.100778_bib1265","doi-asserted-by":"crossref","first-page":"527","DOI":"10.4155\/fmc.16.7","article-title":"Tracking antitumor metallodrugs: promising agents with the Ru(II)- and Fe(II)-cyclopentadienyl scaffolds","volume":"8","author":"Morais","year":"2016","journal-title":"Future Med Chem"},{"key":"10.1016\/j.drup.2021.100778_bib1270","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2015-4484","article-title":"BTP-114: An albumin binding cisplatin prodrug with improved and sustained tumor growth inhibition","volume":"75","author":"Moreau","year":"2015","journal-title":"Cancer Res"},{"key":"10.1016\/j.drup.2021.100778_bib1275","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.ejmech.2019.02.061","article-title":"Polymer \"ruthenium-cyclopentadienyl\" conjugates - New emerging anti-cancer drugs","volume":"168","author":"Moreira","year":"2019","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.drup.2021.100778_bib1280","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1038\/nm1196","article-title":"Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy","volume":"11","author":"Muller","year":"2005","journal-title":"Nature Med"},{"key":"10.1016\/j.drup.2021.100778_bib1285","doi-asserted-by":"crossref","first-page":"599","DOI":"10.2147\/DDDT.S119488","article-title":"Metal complexes in cancer therapy - an update from drug design perspective","volume":"11","author":"Ndagi","year":"2017","journal-title":"Drug Des Dev Ther"},{"key":"10.1016\/j.drup.2021.100778_bib1290","first-page":"3448","article-title":"Crosstalk between apoptosis, necrosis and autophagy","volume":"1833","author":"Nikoletopoulou","year":"2013","journal-title":"Bba-Mol Cell Res"},{"key":"10.1016\/j.drup.2021.100778_bib1295","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1039\/C3MT00341H","article-title":"Mechanism of cellular accumulation of an iridium(III) pentamethylcyclopentadienyl anticancer complex containing a C,N-chelating ligand","volume":"6","author":"Novohradsky","year":"2014","journal-title":"Metallomics"},{"key":"10.1016\/j.drup.2021.100778_bib1300","doi-asserted-by":"crossref","first-page":"3895","DOI":"10.1021\/jm2002074","article-title":"Organometallic Ruthenium(II) Arene Compounds with Antiangiogenic Activity","volume":"54","author":"Nowak-Sliwinska","year":"2011","journal-title":"J Med Chem"},{"key":"10.1016\/j.drup.2021.100778_bib1305","doi-asserted-by":"crossref","first-page":"639","DOI":"10.3892\/br.2016.772","article-title":"Organic cation transporter 6 directly confers resistance to anticancer platinum drugs","volume":"5","author":"Oguri","year":"2016","journal-title":"Biomed Rep"},{"key":"10.1016\/j.drup.2021.100778_bib1310","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.3390\/biom10091336","article-title":"Triapine Derivatives Act as Copper Delivery Vehicles to Induce Deadly Metal Overload in Cancer Cells","volume":"10","author":"Ohui","year":"2020","journal-title":"Biomolecules"},{"key":"10.1016\/j.drup.2021.100778_bib1315","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/S0959-8049(00)00445-7","article-title":"Effects of a novel trinuclear platinum complex in cisplatin-sensitive and cisplatin-resistant human ovarian cancer cell lines: interference with cell cycle progression and induction of apoptosis","volume":"37","author":"Orlandi","year":"2001","journal-title":"Eur J Can"},{"key":"10.1016\/j.drup.2021.100778_bib1320","doi-asserted-by":"crossref","first-page":"6268","DOI":"10.1039\/C8CC02795A","article-title":"A mitochondria-targeting hetero-binuclear Ir(iii)-Pt(ii) complex induces necrosis in cisplatin-resistant tumor cells","volume":"54","author":"Ouyang","year":"2018","journal-title":"Chem Commun"},{"key":"10.1016\/j.drup.2021.100778_bib1325","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.jinorgbio.2011.08.013","article-title":"Overcoming cisplatin resistance using gold(III) mimics: anticancer activity of novel gold(III) polypyridyl complexes","volume":"106","author":"Palanichamy","year":"2012","journal-title":"J Inorg Biochem"},{"key":"10.1016\/j.drup.2021.100778_bib1330","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/nature22379","article-title":"Nutrient acquisition strategies of mammalian cells","volume":"546","author":"Palm","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.drup.2021.100778_bib1335","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.jinorgbio.2014.12.015","article-title":"Synthesis and characterization of the anticancer and metal binding properties of novel pyrimidinylhydrazone derivatives","volume":"144","author":"Pape","year":"2015","journal-title":"J Inorg Biochem"},{"key":"10.1016\/j.drup.2021.100778_bib1340","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.ejmech.2016.03.078","article-title":"Design, synthesis and biological evaluation of thiosemicarbazones, hydrazinobenzothiazoles and arylhydrazones as anticancer agents with a potential to overcome multidrug resistance","volume":"117","author":"Pape","year":"2016","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.drup.2021.100778_bib1345","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1039\/C6MT00105J","article-title":"Copper and conquer: copper complexes of di-2-pyridylketone thiosemicarbazones as novel anti-cancer therapeutics","volume":"8","author":"Park","year":"2016","journal-title":"Metallomics"},{"key":"10.1016\/j.drup.2021.100778_bib1350","doi-asserted-by":"crossref","first-page":"7806","DOI":"10.1002\/chem.201100586","article-title":"Studies of glutathione transferase P1-1 bound to a platinum(IV)-based anticancer compound reveal the molecular basis of its activation","volume":"17","author":"Parker","year":"2011","journal-title":"Chemistry"},{"key":"10.1016\/j.drup.2021.100778_bib1355","doi-asserted-by":"crossref","first-page":"6433","DOI":"10.18632\/oncotarget.14118","article-title":"Resistance to glucose starvation as metabolic trait of platinum-resistant human epithelial ovarian cancer cells","volume":"8","author":"Pasto","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.drup.2021.100778_bib1360","doi-asserted-by":"crossref","first-page":"2550","DOI":"10.1002\/anie.201510551","article-title":"A Potent Glucose-Platinum Conjugate Exploits Glucose Transporters and Preferentially Accumulates in Cancer Cells","volume":"55","author":"Patra","year":"2016","journal-title":"Angew Chem Int Ed Engl"},{"key":"10.1016\/j.drup.2021.100778_bib1365","doi-asserted-by":"crossref","first-page":"9877","DOI":"10.1039\/c1dt10486a","article-title":"Nitroimidazole and glucosamine conjugated heteroscorpionate ligands and related copper(II) complexes. Syntheses, biological activity and XAS studies","volume":"40","author":"Pellei","year":"2011","journal-title":"Dalton Trans"},{"key":"10.1016\/j.drup.2021.100778_bib1370","doi-asserted-by":"crossref","first-page":"45597","DOI":"10.18632\/oncotarget.17316","article-title":"Enhanced antitumor efficacy of cisplatin for treating ovarian cancer in vitro and in vivo via transferrin binding","volume":"8","author":"Peng","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.drup.2021.100778_bib1375","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1002\/ijc.11140","article-title":"Development of resistance to a trinuclear platinum complex in ovarian carcinoma cells","volume":"105","author":"Perego","year":"2003","journal-title":"Int J Can"},{"key":"10.1016\/j.drup.2021.100778_bib1380","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1023\/A:1008265012435","article-title":"Ovarian cancer cisplatin-resistant cell lines: multiple changes including collateral sensitivity to Taxol","volume":"9","author":"Perego","year":"1998","journal-title":"Ann Oncol"},{"key":"10.1016\/j.drup.2021.100778_bib1385","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2020.100718","article-title":"Cancer immunotherapy resistance based on immune checkpoints inhibitors: Targets, biomarkers, and remedies","volume":"53","author":"Perez-Ruiz","year":"2020","journal-title":"Drug Resist Updat"},{"key":"10.1016\/j.drup.2021.100778_bib1390","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/S0891-5849(00)00158-1","article-title":"How important is oxidative damage? Lessons from Alzheimer\u2019s disease","volume":"28","author":"Perry","year":"2000","journal-title":"Free Radic Biol Med"},{"key":"10.1016\/j.drup.2021.100778_bib1395","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1002\/(SICI)1097-0215(19980911)77:6<913::AID-IJC19>3.0.CO;2-1","article-title":"Characterisation of the P53 status, Bcl-2 expression and radiation and platinum drug sensitivity of a panel of human ovarian cancer cell lines","volume":"77","author":"Pestell","year":"1998","journal-title":"Int J Can"},{"key":"10.1016\/j.drup.2021.100778_bib1400","doi-asserted-by":"crossref","first-page":"607","DOI":"10.2174\/0929867324666171116125908","article-title":"Metallodrugs in Targeted Cancer Therapeutics: Aiming at Chemoresistance- related Patterns and Immunosuppressive Tumor Networks","volume":"26","author":"Petanidis","year":"2019","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.drup.2021.100778_bib1405","doi-asserted-by":"crossref","first-page":"2249","DOI":"10.1039\/c3cc39258a","article-title":"Maleimide-functionalised platinum(iv) complexes as a synthetic platform for targeted drug delivery","volume":"49","author":"Pichler","year":"2013","journal-title":"Chem Commun"},{"key":"10.1016\/j.drup.2021.100778_bib1410","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.drup.2012.03.002","article-title":"Collateral sensitivity as a strategy against cancer multidrug resistance","volume":"15","author":"Pluchino","year":"2012","journal-title":"Drug Resist Updat"},{"key":"10.1016\/j.drup.2021.100778_bib1415","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s00280-004-0773-6","article-title":"Cytotoxicity of the organic ruthenium anticancer drug Nami-A is correlated with DNA binding in four different human tumor cell lines","volume":"54","author":"Pluim","year":"2004","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.drup.2021.100778_bib1420","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1039\/C7MT00183E","article-title":"Ferrocene\u2013cinchona hybrids with triazolyl-chalcone linkers act as pro-oxidants and sensitize human cancer cell lines to paclitaxel","volume":"9","author":"Podolski-Reni\u0107","year":"2017","journal-title":"Metallomics"},{"key":"10.1016\/j.drup.2021.100778_bib1425","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1007\/s00280-013-2247-1","article-title":"Molecular and cytogenetic changes in multi-drug resistant cancer cells and their influence on new compounds testing","volume":"72","author":"Podolski-Renic","year":"2013","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.drup.2021.100778_bib1430","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1039\/C6MD00391E","article-title":"Mutual regulation and targeting of multidrug resistance and cancer stem phenotype","volume":"7","author":"Podolski-Renic","year":"2016","journal-title":"MedChemComm"},{"key":"10.1016\/j.drup.2021.100778_bib1435","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1186\/s13059-019-1867-0","article-title":"Correlation of homologous recombination deficiency induced mutational signatures with sensitivity to PARP inhibitors and cytotoxic agents","volume":"20","author":"Poti","year":"2019","journal-title":"Genome Biol"},{"key":"10.1016\/j.drup.2021.100778_bib1440","series-title":"Metal-based Anticancer Agents","first-page":"308","article-title":"Challenges and Chances in the Preclinical to Clinical Translation of Anticancer Metallodrugs","author":"P\u00f6tsch","year":"2019"},{"key":"10.1016\/j.drup.2021.100778_bib1445","doi-asserted-by":"crossref","first-page":"12197","DOI":"10.1039\/C8DT02236D","article-title":"Half-sandwich Os(ii) and Ru(ii) bathophenanthroline complexes: anticancer drug candidates with unusual potency and a cellular activity profile in highly invasive triple-negative breast cancer cells","volume":"47","author":"Pracharova","year":"2018","journal-title":"Dalton Trans"},{"key":"10.1016\/j.drup.2021.100778_bib1450","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1038\/sj.bjc.6690620","article-title":"A novel charged trinuclear platinum complex effective against cisplatin-resistant tumours: hypersensitivity of p53-mutant human tumour xenografts","volume":"80","author":"Pratesi","year":"1999","journal-title":"Br J Cancer"},{"key":"10.1016\/j.drup.2021.100778_bib1455","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.aca.2019.05.064","article-title":"Biological sulphur-containing compounds - Analytical challenges","volume":"1079","author":"Raab","year":"2019","journal-title":"Anal Chim Acta"},{"key":"10.1016\/j.drup.2021.100778_bib1460","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1021\/mp400664t","article-title":"Employing Pancreatic Tumor gamma-Glutamyltransferase for Therapeutic Delivery","volume":"11","author":"Ramsay","year":"2014","journal-title":"Mol Pharm"},{"key":"10.1016\/j.drup.2021.100778_bib1465","doi-asserted-by":"crossref","first-page":"181","DOI":"10.3389\/fphar.2014.00181","article-title":"Glutathione S-conjugates as prodrugs to target drug-resistant tumors","volume":"5","author":"Ramsay","year":"2014","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.drup.2021.100778_bib1470","first-page":"2063","article-title":"cis-Amminedichloro(2-methylpyridine) platinum(II) (AMD473), a novel sterically hindered platinum complex: in vivo activity, toxicology, and pharmacokinetics in mice","volume":"3","author":"Raynaud","year":"1997","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.drup.2021.100778_bib1475","doi-asserted-by":"crossref","first-page":"901","DOI":"10.3389\/fimmu.2020.00901","article-title":"Role of CC Chemokines Subfamily in the Platinum Drugs Resistance Promotion in Cancer","volume":"11","author":"Reyes","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.drup.2021.100778_bib1480","doi-asserted-by":"crossref","DOI":"10.1177\/1758835919839543","article-title":"Overcoming platinum-acquired resistance in ovarian cancer patient-derived xenografts","volume":"11","author":"Ricci","year":"2019","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.drup.2021.100778_bib1485","article-title":"Cisplatin and Oxaliplatin: Our Current Understanding of Their Actions","volume":"18","author":"Riddell","year":"2018","journal-title":"Met Ions Life Sci"},{"key":"10.1016\/j.drup.2021.100778_bib1490","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/s41568-018-0005-8","article-title":"Revisiting the role of ABC transporters in multidrug-resistant cancer","volume":"18","author":"Robey","year":"2018","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.drup.2021.100778_bib1495","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s40268-015-0083-y","article-title":"Auranofin: repurposing an old drug for a golden new age","volume":"15","author":"Roder","year":"2015","journal-title":"Drugs R D"},{"key":"10.1016\/j.drup.2021.100778_bib1500","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1021\/jm3017442","article-title":"The contrasting activity of iodido versus chlorido ruthenium and osmium arene azo- and imino-pyridine anticancer complexes: control of cell selectivity, cross-resistance, p53 dependence, and apoptosis pathway","volume":"56","author":"Romero-Canelon","year":"2013","journal-title":"J Med Chem"},{"key":"10.1016\/j.drup.2021.100778_bib1505","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/s41568-020-00308-y","article-title":"The rediscovery of platinum-based cancer therapy","volume":"21","author":"Rottenberg","year":"2021","journal-title":"Nature Rew Can"},{"key":"10.1016\/j.drup.2021.100778_bib1510","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1186\/s12885-018-4727-5","article-title":"Targeting colorectal cancer cell metabolism through development of cisplatin and metformin nano-cubosomes","volume":"18","author":"Saber","year":"2018","journal-title":"BMC Cancer"},{"key":"10.1016\/j.drup.2021.100778_bib1515","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.critrevonc.2004.09.007","article-title":"Copper transporters regulate the cellular pharmacology and sensitivity to Pt drugs","volume":"53","author":"Safaei","year":"2005","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.drup.2021.100778_bib1520","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1007\/s00280-005-0121-5","article-title":"Modulation of the cellular pharmacology of JM118, the major metabolite of satraplatin, by copper influx and efflux transporters","volume":"57","author":"Samimi","year":"2006","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.drup.2021.100778_bib1525","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.jinorgbio.2010.10.016","article-title":"In vitro antitumour activity of water soluble Cu(I), Ag(I) and Au(I) complexes supported by hydrophilic alkyl phosphine ligands","volume":"105","author":"Santini","year":"2011","journal-title":"J Inorg Biochem"},{"key":"10.1016\/j.drup.2021.100778_bib1530","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1182\/blood-2019-01-894980","article-title":"Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet","volume":"133","author":"Sanz","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.drup.2021.100778_bib1535","doi-asserted-by":"crossref","first-page":"3295","DOI":"10.2147\/CMAR.S200059","article-title":"The beneficial effects of metformin on cancer prevention and therapy: a comprehensive review of recent advances","volume":"11","author":"Saraei","year":"2019","journal-title":"Cancer Manag Res"},{"key":"10.1016\/j.drup.2021.100778_bib1540","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.1172\/JCI118668","article-title":"Redox control of resistance to cis-diamminedichloroplatinum (II) (CDDP): protective effect of human thioredoxin against CDDP-induced cytotoxicity","volume":"97","author":"Sasada","year":"1996","journal-title":"J Clin Invest"},{"key":"10.1016\/j.drup.2021.100778_bib1545","doi-asserted-by":"crossref","first-page":"7144","DOI":"10.1039\/C8DT00686E","article-title":"Dual-acting antitumor Pt(iv) prodrugs of kiteplatin with dichloroacetate axial ligands","volume":"47","author":"Savino","year":"2018","journal-title":"Dalton Trans"},{"key":"10.1016\/j.drup.2021.100778_bib1550","doi-asserted-by":"crossref","first-page":"5518","DOI":"10.1021\/jm300428v","article-title":"Gold(I) carbene complexes causing thioredoxin 1 and thioredoxin 2 oxidation as potential anticancer agents","volume":"55","author":"Schuh","year":"2012","journal-title":"J Med Chem"},{"key":"10.1016\/j.drup.2021.100778_bib1555","doi-asserted-by":"crossref","first-page":"3796","DOI":"10.1074\/jbc.M115.682450","article-title":"Glucose Modulation Induces Lysosome Formation and Increases Lysosomotropic Drug Sequestration via the P-Glycoprotein Drug Transporter","volume":"291","author":"Seebacher","year":"2016","journal-title":"J Biol Chem"},{"key":"10.1016\/j.drup.2021.100778_bib1560","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2020.100712","article-title":"Inhibiting the inhibitors: Targeting anti-apoptotic proteins in cancer and therapy resistance","volume":"52","author":"Shahar","year":"2020","journal-title":"Drug Resist Updat"},{"key":"10.1016\/j.drup.2021.100778_bib1565","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1016\/S0959-8049(02)00244-7","article-title":"Retention of activity by the new generation platinum agent AMD0473 in four human tumour cell lines possessing acquired resistance to oxaliplatin","volume":"38","author":"Sharp","year":"2002","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.drup.2021.100778_bib1570","doi-asserted-by":"crossref","first-page":"3270","DOI":"10.1016\/j.jprot.2012.03.044","article-title":"Quantitative immunoproteomics analysis reveals novel MHC class I presented peptides in cisplatin-resistant ovarian cancer cells","volume":"75","author":"Shetty","year":"2012","journal-title":"J Proteomics"},{"key":"10.1016\/j.drup.2021.100778_bib1575","doi-asserted-by":"crossref","first-page":"119","DOI":"10.4155\/fmc-2018-0248","article-title":"Metal-based antitumor compounds: beyond cisplatin","volume":"11","author":"Simpson","year":"2019","journal-title":"Future Med Chem"},{"key":"10.1016\/j.drup.2021.100778_bib1580","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1158\/0008-5472.CAN-06-1538","article-title":"An organometallic protein kinase inhibitor pharmacologically activates p53 and induces apoptosis in human melanoma cells","volume":"67","author":"Smalley","year":"2007","journal-title":"Cancer Res"},{"key":"10.1016\/j.drup.2021.100778_bib1585","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1158\/1535-7163.1543.3.12","article-title":"Role of human copper transporter Ctr1 in the transport of platinum-based antitumor agents in cisplatin-sensitive and cisplatin-resistant cells","volume":"3","author":"Song","year":"2004","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.drup.2021.100778_bib1590","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.ejmech.2017.06.038","article-title":"Cyclometalated iridium(III)-guanidinium complexes as mitochondria-targeted anticancer agents","volume":"138","author":"Song","year":"2017","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.drup.2021.100778_bib1595","doi-asserted-by":"crossref","first-page":"14376","DOI":"10.1073\/pnas.97.26.14376","article-title":"An alternative, nonapoptotic form of programmed cell death","volume":"97","author":"Sperandio","year":"2000","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.drup.2021.100778_bib1600","doi-asserted-by":"crossref","first-page":"15584","DOI":"10.3390\/molecules191015584","article-title":"Cellular transport mechanisms of cytotoxic metallodrugs: an overview beyond cisplatin","volume":"19","author":"Spreckelmeyer","year":"2014","journal-title":"Molecules"},{"key":"10.1016\/j.drup.2021.100778_bib1605","doi-asserted-by":"crossref","first-page":"8601","DOI":"10.1021\/acs.jmedchem.6b01050","article-title":"Structure-Activity Relationships of Di-2-pyridylketone, 2-Benzoylpyridine, and 2-Acetylpyridine Thiosemicarbazones for Overcoming Pgp-Mediated Drug Resistance","volume":"59","author":"Stacy","year":"2016","journal-title":"J Med Chem"},{"key":"10.1016\/j.drup.2021.100778_bib1610","doi-asserted-by":"crossref","first-page":"6074","DOI":"10.2174\/0929867325666180607094856","article-title":"Dual Inhibitors as a New Challenge for Cancer Multidrug Resistance Treatment","volume":"26","author":"Stankovic","year":"2018","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.drup.2021.100778_bib1615","doi-asserted-by":"crossref","DOI":"10.1002\/aoc.4246","article-title":"Cell-based studies of the first-in-class half-sandwich Ir(III) complex containing histone deacetylase inhibitor 4-phenylbutyrate","volume":"32","author":"Starha","year":"2018","journal-title":"Appl Organomet Chem"},{"key":"10.1016\/j.drup.2021.100778_bib1620","doi-asserted-by":"crossref","DOI":"10.3390\/molecules23020420","article-title":"Half-Sandwich Ru(II) and Os(II) Bathophenanthroline Complexes Containing a Releasable Dichloroacetato Ligand","volume":"23","author":"Starha","year":"2018","journal-title":"Molecules"},{"key":"10.1016\/j.drup.2021.100778_bib1625","doi-asserted-by":"crossref","first-page":"12669","DOI":"10.1021\/ic201801e","article-title":"Conjugation of organoruthenium (II) 3-(1 H-benzimidazol-2-yl) pyrazolo [3, 4-b] pyridines and indolo [3, 2-d] benzazepines to recombinant human serum albumin: a strategy to enhance cytotoxicity in cancer cells","volume":"50","author":"Stepanenko","year":"2011","journal-title":"Inorg Chem"},{"key":"10.1016\/j.drup.2021.100778_bib1630","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1124\/mol.112.079657","article-title":"The anticancer ruthenium complex KP1019 induces DNA damage, leading to cell cycle delay and cell death in Saccharomyces cerevisiae","volume":"83","author":"Stevens","year":"2013","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.drup.2021.100778_bib1635","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.critrevonc.2007.02.001","article-title":"Mechanisms of resistance to cisplatin and carboplatin","volume":"63","author":"Stewart","year":"2007","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.drup.2021.100778_bib1640","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.drup.2018.05.001","article-title":"How mutations shape p53 interactions with the genome to promote tumorigenesis and drug resistance","volume":"38","author":"Stiewe","year":"2018","journal-title":"Drug Resist Updat"},{"key":"10.1016\/j.drup.2021.100778_bib1645","doi-asserted-by":"crossref","first-page":"16036","DOI":"10.18632\/oncotarget.13917","article-title":"The association between copper transporters and the prognosis of cancer patients undergoing chemotherapy: a meta-analysis of literatures and datasets","volume":"8","author":"Sun","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.drup.2021.100778_bib1650","doi-asserted-by":"crossref","first-page":"2967","DOI":"10.1021\/ja511978y","article-title":"Necroptosis-inducing rhenium(V) oxo complexes","volume":"137","author":"Suntharalingam","year":"2015","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.drup.2021.100778_bib1655","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1039\/C3MT00364G","article-title":"A dual-targeting, p53-independent, apoptosis-inducing platinum(II) anticancer complex, [Pt(BDIQQ)]Cl","volume":"6","author":"Suntharalingam","year":"2014","journal-title":"Metallomics"},{"key":"10.1016\/j.drup.2021.100778_bib1660","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1007\/s00428-005-1228-0","article-title":"Augmented expression of metallothionein and glutathione S-transferase pi as unfavourable prognostic factors in cisplatin-treated ovarian cancer patients","volume":"447","author":"Surowiak","year":"2005","journal-title":"Virchows Archiv"},{"key":"10.1016\/j.drup.2021.100778_bib1665","doi-asserted-by":"crossref","first-page":"5753","DOI":"10.1021\/cr4006236","article-title":"Targeting the Achilles heel of multidrug-resistant cancer by exploiting the fitness cost of resistance","volume":"114","author":"Szakacs","year":"2014","journal-title":"Chem Rev"},{"key":"10.1016\/j.drup.2021.100778_bib1670","first-page":"794","article-title":"Production of large amounts of hydrogen peroxide by human tumor cells","volume":"51","author":"Szatrowski","year":"1991","journal-title":"Cancer Res"},{"key":"10.1016\/j.drup.2021.100778_bib1675","doi-asserted-by":"crossref","first-page":"14164","DOI":"10.1039\/C7DT02887C","article-title":"The cytotoxicity and mechanism of action of new multinuclear Scaffold Au(III), Pd(II) pincer complexes containing a bis(diphenylphosphino) ferrocene\/non-ferrocene ligand","volume":"46","author":"Tabrizi","year":"2017","journal-title":"Dalton Trans"},{"key":"10.1016\/j.drup.2021.100778_bib1680","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s10637-009-9235-7","article-title":"Augmented antitumor effects of combination therapy of cisplatin with ethaselen as a novel thioredoxin reductase inhibitor on human A549 cell in vivo","volume":"28","author":"Tan","year":"2010","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.drup.2021.100778_bib1685","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1186\/1471-2407-13-237","article-title":"Anti-cancer effects of newly developed chemotherapeutic agent, glycoconjugated palladium (II) complex, against cisplatin-resistant gastric cancer cells","volume":"13","author":"Tanaka","year":"2013","journal-title":"BMC Cancer"},{"key":"10.1016\/j.drup.2021.100778_bib1690","doi-asserted-by":"crossref","first-page":"24306","DOI":"10.1074\/jbc.M109.026583","article-title":"The thioxotriazole copper(II) complex A0 induces endoplasmic reticulum stress and paraptotic death in human cancer cells","volume":"284","author":"Tardito","year":"2009","journal-title":"J Biol Chem"},{"key":"10.1016\/j.drup.2021.100778_bib1695","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1039\/D0QI01344G","article-title":"Unprecedented collateral sensitivity for cisplatin-resistant lung cancer cells presented by new ruthenium organometallic compounds","volume":"8","author":"Teixeira","year":"2021","journal-title":"Inorg Chem Front"},{"key":"10.1016\/j.drup.2021.100778_bib1700","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1038\/onc.2009.356","article-title":"Immunogenic death of colon cancer cells treated with oxaliplatin","volume":"29","author":"Tesniere","year":"2010","journal-title":"Oncogene"},{"key":"10.1016\/j.drup.2021.100778_bib1705","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1054\/drup.1999.0086","article-title":"GST function in drug and stress response","volume":"2","author":"Tew","year":"1999","journal-title":"Drug Resist Updat"},{"key":"10.1016\/j.drup.2021.100778_bib1710","doi-asserted-by":"crossref","first-page":"17862","DOI":"10.1038\/s41598-018-35860-z","article-title":"DEBIO 1143, an IAP inhibitor, reverses carboplatin resistance in ovarian cancer cells and triggers apoptotic or necroptotic cell death","volume":"8","author":"Thibault","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.drup.2021.100778_bib1715","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.ccell.2018.03.012","article-title":"T Cell Dysfunction in Cancer","volume":"33","author":"Thommen","year":"2018","journal-title":"Cancer Cell"},{"key":"10.1016\/j.drup.2021.100778_bib1720","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.jinorgbio.2012.06.016","article-title":"[Ru-II(eta(5)-C5H5)(bipy)(PPh3)](+), a promising large spectrum antitumor agent: Cytotoxic activity and interaction with human serum albumin","volume":"117","author":"Tomaz","year":"2012","journal-title":"J Inorg Biochem"},{"key":"10.1016\/j.drup.2021.100778_bib1725","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1038\/nrc3495","article-title":"Iron and cancer: more ore to be mined","volume":"13","author":"Torti","year":"2013","journal-title":"Nature Rev Cancer"},{"key":"10.1016\/j.drup.2021.100778_bib1730","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/S0076-6879(05)01019-0","article-title":"Glutathione S-transferases as regulators of kinase pathways and anticancer drug targets","volume":"401","author":"Townsend","year":"2005","journal-title":"Methods Enzymol"},{"key":"10.1016\/j.drup.2021.100778_bib1735","doi-asserted-by":"crossref","first-page":"2925","DOI":"10.1039\/C3SC53243G","article-title":"NKP-1339, the first ruthenium-based anticancer drug on the edge to clinical application","volume":"5","author":"Trondl","year":"2014","journal-title":"Chem Sci"},{"key":"10.1016\/j.drup.2021.100778_bib1740","doi-asserted-by":"crossref","first-page":"8293","DOI":"10.1158\/0008-5472.CAN-09-2422","article-title":"Identification of compounds selectively killing multidrug-resistant cancer cells","volume":"69","author":"Turk","year":"2009","journal-title":"Cancer Res"},{"key":"10.1016\/j.drup.2021.100778_bib1745","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1111\/j.1349-7006.1999.tb00767.x","article-title":"Differences in substrate specificity among glutathione conjugates (GS-X) pump family members: comparison between multidrug resistance-associated protein and a novel transporter expressed on a cisplatin-resistant cell line (KCP-4)","volume":"90","author":"Ueda","year":"1999","journal-title":"Jpn J Cancer Res"},{"key":"10.1016\/j.drup.2021.100778_bib1750","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.jinorgbio.2013.07.002","article-title":"First polymer \u201cruthenium-cyclopentadienyl\u201d complex as potential anticancer agent","volume":"127","author":"Valente","year":"2013","journal-title":"J Inorg Biochem"},{"key":"10.1016\/j.drup.2021.100778_bib1755","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1002\/cmdc.200900370","article-title":"Anticancer Therapeutics That Target Selenoenzymes: Synthesis, Characterization, in vitro Cytotoxicity, and Thioredoxin Reductase Inhibition of a Series of Gold(I) Complexes Containing Hydrophilic Phosphine Ligands","volume":"5","author":"Vergara","year":"2010","journal-title":"ChemMedChem"},{"key":"10.1016\/j.drup.2021.100778_bib1760","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1002\/ijc.2910610317","article-title":"Resistance-associated factors in human small-cell lung-carcinoma GLC4 sub-lines with increasing adriamycin resistance","volume":"61","author":"Versantvoort","year":"1995","journal-title":"Int J Cancer"},{"key":"10.1016\/j.drup.2021.100778_bib1765","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.1021\/jm070039f","article-title":"Development of ruthenium antitumor drugs that overcome multidrug resistance mechanisms","volume":"50","author":"Vock","year":"2007","journal-title":"J Med Chem"},{"key":"10.1016\/j.drup.2021.100778_bib1770","first-page":"799","article-title":"Doxorubicin-gallium-transferrin conjugate overcomes multidrug resistance: evidence for drug accumulation in the nucleus of drug resistant MCF-7\/ADR cells","volume":"20","author":"Wang","year":"2000","journal-title":"Anticancer Res"},{"key":"10.1016\/j.drup.2021.100778_bib1775","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.inoche.2015.08.013","article-title":"A cyclometalated iridium(III) complex that induces apoptosis in cisplatin-resistant cancer cells","volume":"61","author":"Wang","year":"2015","journal-title":"Inorg Chem Commun"},{"key":"10.1016\/j.drup.2021.100778_bib1780","doi-asserted-by":"crossref","first-page":"100743","DOI":"10.1016\/j.drup.2021.100743","article-title":"Multidrug resistance proteins (MRPs): Structure, function and the overcoming of cancer multidrug resistance","volume":"54","author":"Wang","year":"2021","journal-title":"Drug Resist Updat"},{"key":"10.1016\/j.drup.2021.100778_bib1785","doi-asserted-by":"crossref","first-page":"5392","DOI":"10.1039\/C9RA10357K","article-title":"Unveiling the anti-cancer mechanism for half-sandwich and cyclometalated Ir(III)-based complexes with functionalized alpha-lipoic acid","volume":"10","author":"Wang","year":"2020","journal-title":"RSC Adv"},{"key":"10.1016\/j.drup.2021.100778_bib1790","doi-asserted-by":"crossref","first-page":"3426","DOI":"10.1002\/anie.201800422","article-title":"A Cisplatin-Loaded Immunochemotherapeutic Nanohybrid Bearing Immune Checkpoint Inhibitors for Enhanced Cervical Cancer Therapy","volume":"57","author":"Wang","year":"2018","journal-title":"Angew Chem Int Ed Engl"},{"key":"10.1016\/j.drup.2021.100778_bib1795","first-page":"1071","article-title":"Profiling of apoptosis- and autophagy-associated molecules in human lung cancer A549 cells in response to cisplatin treatment using stable isotope labeling with amino acids in cell culture","volume":"54","author":"Wang","year":"2019","journal-title":"Int J Oncol"},{"key":"10.1016\/j.drup.2021.100778_bib1800","first-page":"383","article-title":"Human sarcoma cell lines MES-SA and MES-SA\/Dx5 as a model for multidrug resistance modulators screening","volume":"25","author":"Wesolowska","year":"2005","journal-title":"Anticancer Res"},{"key":"10.1016\/j.drup.2021.100778_bib1805","doi-asserted-by":"crossref","first-page":"3108","DOI":"10.1002\/chem.201405467","article-title":"On the stability of Pt(IV) pro-drugs with haloacetato ligands in the axial positions","volume":"21","author":"Wexselblatt","year":"2015","journal-title":"Chemistry"},{"key":"10.1016\/j.drup.2021.100778_bib1810","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.jconrel.2016.11.005","article-title":"Co-delivery of polymeric metformin and cisplatin by self-assembled core-membrane nanoparticles to treat non-small cell lung cancer","volume":"244","author":"Xiong","year":"2016","journal-title":"J Control Release"},{"key":"10.1016\/j.drup.2021.100778_bib1815","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1007\/s10555-017-9687-8","article-title":"EGFR-targeted therapies in the post-genomic era","volume":"36","author":"Xu","year":"2017","journal-title":"Cancer Metast Rev"},{"key":"10.1016\/j.drup.2021.100778_bib1820","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1080\/10428194.2017.1346253","article-title":"Arsenic trioxide decreases the amount and inhibits the function of regulatory T cells, which may contribute to its efficacy in the treatment of acute promyelocytic leukemia","volume":"59","author":"Xu","year":"2018","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.drup.2021.100778_bib1825","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1021\/mp200571k","article-title":"Mitaplatin Increases Sensitivity of Tumor Cells to Cisplatin by Inducing Mitochondrial Dysfunction","volume":"9","author":"Xue","year":"2012","journal-title":"Mol Pharm"},{"key":"10.1016\/j.drup.2021.100778_bib1830","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1039\/C5BM00439J","article-title":"Polymer nanoparticle delivery of dichloroacetate and DACH-Pt to enhance antitumor efficacy and lower systemic toxicity","volume":"4","author":"Yang","year":"2016","journal-title":"Biomater Sci"},{"key":"10.1016\/j.drup.2021.100778_bib1835","doi-asserted-by":"crossref","first-page":"15166","DOI":"10.1002\/chem.201703157","article-title":"Valproic Acid-Functionalized Cyclometalated Iridium(III) Complexes as Mitochondria-Targeting Anticancer Agents","volume":"23","author":"Ye","year":"2017","journal-title":"Chemistry"},{"key":"10.1016\/j.drup.2021.100778_bib1840","doi-asserted-by":"crossref","first-page":"7800","DOI":"10.1002\/chem.201505160","article-title":"Mono- and Dinuclear Phosphorescent Rhenium(I) Complexes: Impact of Subcellular Localization on Anticancer Mechanisms","volume":"22","author":"Ye","year":"2016","journal-title":"Chemistry"},{"key":"10.1016\/j.drup.2021.100778_bib1845","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1631\/jzus.B1600073","article-title":"Ethaselen: a novel organoselenium anticancer agent targeting thioredoxin reductase 1 reverses cisplatin resistance in drug-resistant K562 cells by inducing apoptosis","volume":"18","author":"Ye","year":"2017","journal-title":"J Zhejiang Univ-Sc B"},{"key":"10.1016\/j.drup.2021.100778_bib1850","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s40259-018-0291-4","article-title":"Indoleamine 2,3-Dioxygenase (IDO) Inhibition as a Strategy to Augment Cancer Immunotherapy","volume":"32","author":"Yentz","year":"2018","journal-title":"BioDrugs"},{"key":"10.1016\/j.drup.2021.100778_bib1855","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.3390\/molecules23061410","article-title":"Gold-Based Medicine: A Paradigm Shift in Anti-Cancer Therapy?","volume":"23","author":"Yeo","year":"2018","journal-title":"Molecules"},{"key":"10.1016\/j.drup.2021.100778_bib1860","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nrm2308","article-title":"The BCL-2 protein family: opposing activities that mediate cell death","volume":"9","author":"Youle","year":"2008","journal-title":"Nat Rev Mol Cell Bio"},{"key":"10.1016\/j.drup.2021.100778_bib1865","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1124\/mol.116.107409","article-title":"Thiosemicarbazones Functioning as Zinc Metallochaperones to Reactivate Mutant p53","volume":"91","author":"Yu","year":"2017","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.drup.2021.100778_bib1870","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jinorgbio.2015.12.003","article-title":"Potentiation of mitochondrial dysfunction in tumor cells by conjugates of metabolic modulator dichloroacetate with a Pt(IV) derivative of oxaliplatin","volume":"156","author":"Zajac","year":"2016","journal-title":"J Inorg Biochem"},{"key":"10.1016\/j.drup.2021.100778_bib1875","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1158\/1535-7163.MCT-18-1080","article-title":"Combinatorial Therapy of Zinc Metallochaperones with Mutant p53 Reactivation and Diminished Copper Binding","volume":"18","author":"Zaman","year":"2019","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.drup.2021.100778_bib1880","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1158\/1541-7786.MCR-19-1145","article-title":"Mitochondria Participate in Chemoresistance to Cisplatin in Human Ovarian Cancer Cells","volume":"18","author":"Zampieri","year":"2020","journal-title":"Mol Cancer Res"},{"key":"10.1016\/j.drup.2021.100778_bib1885","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1002\/cmdc.201100426","article-title":"Evaluation of platinum-ethacrynic acid conjugates in the treatment of mesothelioma","volume":"6","author":"Zanellato","year":"2011","journal-title":"ChemMedChem"},{"key":"10.1016\/j.drup.2021.100778_bib1890","doi-asserted-by":"crossref","first-page":"3833","DOI":"10.1039\/C9CC00882A","article-title":"An organoruthenium complex overcomes ABCG2-mediated multidrug resistance via multiple mechanisms","volume":"55","author":"Zeng","year":"2019","journal-title":"Chem Commun"},{"key":"10.1016\/j.drup.2021.100778_bib1895","doi-asserted-by":"crossref","first-page":"19449","DOI":"10.1038\/srep19449","article-title":"Ruthenium(II) Complexes with 2-Phenylimidazo[4,5-f][1,10] phenanthroline Derivatives that Strongly Combat Cisplatin-Resistant Tumor Cells","volume":"6","author":"Zeng","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.drup.2021.100778_bib1900","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1016\/j.tips.2017.06.001","article-title":"Targeting the Thioredoxin System for Cancer Therapy","volume":"38","author":"Zhang","year":"2017","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.drup.2021.100778_bib1905","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1002\/iub.2043","article-title":"Chemoresistance in mesenchymal lung cancer cells is correlated to high regulatory T cell presence in the tumor microenvironment","volume":"71","author":"Zhang","year":"2019","journal-title":"Iubmb Life"},{"key":"10.1016\/j.drup.2021.100778_bib1910","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1097\/CAD.0000000000000234","article-title":"A hybrid platinum drug dichloroacetate-platinum(II) overcomes cisplatin drug resistance through dual organelle targeting","volume":"26","author":"Zhang","year":"2015","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.drup.2021.100778_bib1915","doi-asserted-by":"crossref","first-page":"8790","DOI":"10.1021\/ja5038269","article-title":"Pt(IV) Prodrugs Designed to Bind Non-Covalently to Human Serum Albumin for Drug Delivery","volume":"136","author":"Zheng","year":"2014","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.drup.2021.100778_bib1920","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.drup.2015.11.004","article-title":"Lysosomes as mediators of drug resistance in cancer","volume":"24","author":"Zhitomirsky","year":"2016","journal-title":"Drug Resist Updat"},{"key":"10.1016\/j.drup.2021.100778_bib1925","doi-asserted-by":"crossref","first-page":"343","DOI":"10.3389\/fphar.2020.00343","article-title":"The Drug-Resistance Mechanisms of Five Platinum-Based Antitumor Agents","volume":"11","author":"Zhou","year":"2020","journal-title":"Front Pharmacol"}],"container-title":["Drug Resistance Updates"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1368764621000364?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1368764621000364?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T04:58:03Z","timestamp":1761281883000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1368764621000364"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":385,"alternative-id":["S1368764621000364"],"URL":"https:\/\/doi.org\/10.1016\/j.drup.2021.100778","relation":{},"ISSN":["1368-7646"],"issn-type":[{"value":"1368-7646","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Metal- and metalloid-based compounds to target and reverse cancer multidrug resistance","name":"articletitle","label":"Article Title"},{"value":"Drug Resistance Updates","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drup.2021.100778","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100778"}}